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ABSTRACT
Therapeutic thrombolysis with plasminogen activators is an effective and 
potentially life-saving measure in the management of patients with acute myocardial 
infarction and cerebral ischemia. Liposomal encapsulation of plasminogen activators by 
multiple laboratories around the world has shown promise. However, liposomes suffer 
&om physical instability that results in a short shelf-life. The use of polymer 
microcapsules as an encapsulation vehicle has now demonstrated comparable, if not 
superior, thrombolytic potential compared to liposomes with improved storage capability.
The capacity of liposomal (LESK) and microencapsulated streptokinase (MESK) 
to digest an occlusive arterial thrombus were compared to an identical dosage of 6ee 
streptokinase (FREE SK) in a rabbit model of carotid thrombosis (Chapter 3). Compared 
to FREE SK (74.5 ± 16.9 min; mean ± SEM), LESK demonstrated signiGcantly reduced 
reperfusion times (19.3 ± 4.6 min) while MESK exhibited even greater improvement (7.3 
±1.6 min). LESK and MESK also resulted in reduced residual clot mass and greater 
return of arterial blood flow.
In vitro studies utilizing clots formed of whole blood or plasma in glass capillary 
tubes were completed to elucidate the mechanism of lysis with MESK (Chapter 4). In 
both clot types, lysis occurred more rapidly at higher pressures and MESK restored flow
f^ te r than FREE SK. Light and confbcal microscopies were used to capture images of 
clot digestion. FREE SK, like other free plasminogen activators, binds to the leading 
edge of the thrombus and initiates digestion through a series of localized reactions at the 
&ont. MESK, however, accelerates digestion by improving the distribution of 
streptokinase throughout the clot following greater penetration of the leading edge, a 
finding confirmed by a computer simulation (Chapter 5). Clot digestion occurs within 
the thrombus and at the front, thereby promoting faster clot digestion and restoration of 
flow.
The potential benefit of MESK was also explored in a canine model of coronary 
thrombosis, a clinically relevant model of myocardial infarction. Compared to FREE SK 
(68 ± 7 min), MESK significantly reduced the time to achieve sustained reperfusion of 
the occluded artery (29 ± 4 min). In addition, MESK-treatment resulted in substantial
reductions in infarct size, residual clot mass, and bleeding complications.
MESK accelerates thrombolysis and the restoration of blood flow compared to 
identical dosages of FREE SK while also reducing systemic fibrinogenolysis and blood 
loss. Accelerated clot digestion is achieved by distributed intraclot thrombolysis 
following greater spatial distribution of the plasminogen activator. Microencapsulation 
may produce an improved dosage form for restoring arterial blood flow and reducing 
bleeding complications with thrombolytic therapy.
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DEVELOPMENT AND CHARACTERIZATION OF ENCAPSULATED 
THROMBOLYTIC FORMULATIONS TO ENHANCE THROMBOLYSIS
CHAPTER 1
INTRODUCTION
Cardiovascular disease continues to be the primary cause of death in the Western 
world. Accounting for nearly 950,000 deaths (40% of total mortality) and $352 billion in 
medical expenditures annually, cardiovascular disease has a profound effect on all races 
and genders [1]. Although cardiovascular disease has a greater effect on the older 
generation, an increasing trend in younger victims of such crises is now being reported. 
CVD ends more lives each year than the next 5 leading causes of death combined; more 
than cancer, chronic lower respiratory diseases, accidents, diabetes mellitus, and 
influenza and pneumonia. Given the number of overweight Americans and the size of 
the aging population, CVD is likely to be a significant problem for years to come [2].
When considering the multiple causes of death within CVD, it is clear that 
coronary heart disease is a mzyor player. More than one-half of all deaths attributed to 
CVD can be linked to coronary heart disease, with another 18% due to stroke. As a large 
percentage of events related to coronary heart disease and stroke are ischemic in nature, 
improved therapies to digest occlusive clots must be pursued in order to upgrade the 
prognosis of afflicted patients.
Effective reperfusion therapy is required to restore vessel patency quickly and 
reperfuse tissue once patients realize symptoms of occlusive crises. Reperfusion therapy 
is primarily composed of three methods: 1) thrombolytic therapy to digest the thrombus 
and restore blood flow; 2) percutaneous transluminal coronary angioplasty (PTCA) to 
push back atherosclerotic plaque that is limiting the cross-sectional area available for 
blood flow; and 3) stent placement to assure that the vessel remains open [3]. The use of 
each treatment modality requires various levels of clinical screening, trained personnel, 
and equipment.
Thrombolytic therapy is available as a means to dissolve the occlusive thrombus 
and achieve patency. Prior to infusion, the patient must be cleared of contraindications 
for plasminogen activators. For stroke victims, the type of stroke must be verified as 
ischemic in nature (and not hemorrhagic which is a contraindication for thrombolysis) by 
MRI or CT scan. Other contraindications include age over 75 years, recent surgery that 
might be complicated due to the potential for bleeding, and presentation for treatment 
after the recommended 3-6 or 6-12 hour windows for stroke or myocardial infarction, 
respectively. If the patient does not present any contraindications, the agent can be 
administered intravenously by personnel trained in initiating and monitoring intravenous
fluids. In contrast, angioplasty and stent placement require numerous specialized persons 
such as cardiologists, radiologists, nurses, and technicians to operate the equipment.
The benefits of thrombolytic therapy compared to angioplasty have been explored 
[4, 5]. Reviews of large trials have demonstrated an improvement in mortality, infarct 
size, and left ventricular function when patients receive angioplasty instead of 
thrombolytic therapy soon after symptoms arise. Other studies have examined the cost- 
to-benefit ratio of each therapy and found comparable results [6, 7]. Despite the reported 
benefit, only 20% of American clinics are currently outfitted with the necessary resources 
to provide angioplasty to a patient presenting with symptoms of an occlusive thrombus 
[7]. While it is thought that thrombolytic therapy and angioplasty can work effectively in 
concert, the consensus among physicians is that both therapies are effective and, barring 
contraindications, the therapy most readily available should be administered in order to 
restore blood flow quickly.
Thrombolytic therapy is characterized by the administration of medicinal agents, 
commonly referred to as "clot-busting" drugs, which initiate a cascade of events within 
the patient's own circulatory system to dissolve the thrombus and restore blood flow [8]. 
Two types of plasminogen activators are available: 1) indirect activators {streptokinase 
and staphylokinase} and 2) direct activators {tissue-type plasminogen activators (t-PA) 
and its numerous genetic variants, bat plasminogen activator, and urokinase}. While 
direct activators are potent, stand alone agents, indirect activators must first complex with 
plasminogen, a circulating plasma protein, and the corqugate actually serves as the 
plasminogen activator. The protein-plasminogen complex then combines with and
cleaves plasminogen, resulting in a protease known as plasmin. Plasmin can, in turn, 
digest the fibrin strands that provide structural integrity for the thrombus.
Successful thrombolytic therapy must overcome physiologic obstacles once 
infused for conversion of plasminogen to plasmin and subsequent clot digestion. First, 
plasminogen activator inhibitors such as PAI-I act to neutralize the concentration of clot- 
busting drug which is present in the circulation. Additionally, circulating antibodies 
could potentially be present that could neutralize or deactivate a plasminogen activator of 
bacterial origin such as streptokinase or staphylokinase. Between 10 and 20% of the 
American population has reported substantial antibody titers to streptococcal or 
staphylococcal bacteria that could significantly affect the success of streptokinase or 
staphylokinase for thrombolytic therapy [9]. The three largest studies examining the 
effect of antibody titers on the success or thrombolytic therapy with streptokinase do not 
agree on the significance of high titers [10-12], with some reporting inhibition and others 
reporting no effect. Finally, once plasmin is formed from the cleavage of plasminogen, it 
is rapidly neutralized in the circulation by a 2-antiplasmin. The enzyme remains briefly 
with a reported half-life of 0.1 s in the circulation but 2 orders of magnitude greater when 
bound to fibrin [13].
Thrombolytic therapy has several limitations including its effect on numerous 
other circulating species. For example, substantial depletions of plasma proteins such as 
plasminogen (the driving force for thrombolytic therapy) and fibrinogen (which plays an 
integral role in the clotting process) have been routinely reported when utilizing 
plasminogen activators [14-17]. The reduction in plasminogen occurs primarily due to 
the conversion of plasminogen to plasmin. Additionally, clot-bound plasminogen
migrates into the free circulation due to the concentration gradient that is established 
during this process, a phenomenon described by Sobel et al. termed "plasminogen steal" 
[18]. Fibrinogenolysis (the breakdown of fibrinogen) has been reported by several 
investigators as well, which has resulted in increased bleeding tendencies for subjects 
receiving thrombolytic therapy [16,17]. These issues must be considered to promote 
successfiil reperfusion therapy with plasminogen activators.
Despite the clear benefits that can be achieved, thrombolytic therapy is 
dramatically underutilized with less than 75% of eligible AMI patients and only 5-7% of 
eligible stroke patients receiving thrombolytic therapy [19,20]. Possible reasons for 
underutilization include physician preference, patient contraindications, seeking 
treatment outside of the accepted treatment window, less than optimal results, the 
potential for bleeding complications, and cost. Factors such as physician preference and 
patient arrival at the emergency room can be addressed through education, public 
awareness, and instilling a sense of urgency to seek treatment upon symptom 
presentation. Other issues such as efficacy and bleeding complications are targeted for 
improvement by the administration of encapsulated plasminogen activators. For the 40- 
60% of patients who do not achieve vascular patency after thrombolytic therapy [21], 
additional reperfusion therapy must be administered such as angioplasty or, in extreme 
cases, coronary artery bypass graft surgery.
Since the first in vivo study reporting accelerated thrombolysis with encapsulated 
streptokinase in 1990 [22], other reports have demonstrated improvements in multiple 
endpoints when using encapsulated plasminogen activators compared to identical dosages 
of nonencapsulated agents. Laboratories in China [23], the Netherlands [24], and the
United States [25] have each reported enhanced clot lysis m vitro and in vivo with 
encapsulated plasminogen activators (Chapter 2). However, each of these studies has 
utilized the liposome, an aggregate of biological molecules formed of phospholipids. 
Although the results have been promising, liposomes possess limited stability and often 
require a lengthy preparation time [26]. For these reasons, this study has turned its focus 
towards the development of a more stable formulation of encapsulated plasminogen 
activator that provides similar or improved benefit to that observed with liposomal 
encapsulated agents.
The purpose of this research is to determine if the administration of a 
plasminogen activator encapsulated in polymer microcapsules could provide similar 
improvement in thrombolysis as seen with liposomal encapsulated plasminogen 
activators while possessing improved stability and hence, extended shelf-life. This study 
characterizes the ability of an encapsulated plasminogen activator to digest occlusive 
thrombi both in vivo and in vitro while exploring the mechanism of its success.
Previous studies examining the benefit of liposomal encapsulated plasminogen 
activators are reviewed in Chapter 2. Early work in this study utilizing liposomal 
encapsulated streptokinase (LESK) in a rabbit model of carotid thrombosis is described in 
Chapter 3. The first generation of microencapsulated streptokinase (MESK) was directly 
compared to identical dosages of LESK and 6ee streptokinase (FREE SK) in a rabbit 
model to explore the efficacy of such a formulation.
In vitro characterization was initialized to clarify the mechanism of clot lysis with 
MESK. A simple in vitro system previously described by others [27,28] was employed 
to examine encapsulated formulations' ability to digest thrombi formed of either whole
blood or human plasma while varying the applied pressure (Chapter 4). Microscopic 
techniques including light microscopy, real-time video of light microscopy, and laser 
scanning confbcal microscopy were then used to explore the mechanism of clot lysis.
Lysis with both unencapsulated and encapsulated streptokinase has been 
approximated by a numerical model based on the convection-diffusion equation. A 
modiGed convection-diffusion equation has been utilized which includes numerous 
reactions as well as a Langmuirian-type isotherm to describe the adsorption phenomena. 
These results are described in Chapter 5.
Finally, the potential beneSt of MESK was examined in a clinically relevant 
animal model. A canine model of coronary artery thrombosis was used to approximate 
the condition of acute myocardial infarction. Multiple endpoints were followed in the 
canine model including initial and sustained reperfusion times, residual clot mass, infarct 
mass, reocclusion episodes, and bleeding complications. These results are described in 
Chapter 6.
PREVIOUS ATTEMPTS TO ACHIEVE ENHANCED THROMBOLYSIS
CHAPTER 2
INTRODUCTION
As an alternative to invasive techniques such as angioplasty or bypass graA 
surgery, myocardial infarction and stroke can be treated medicinally with plasminogen 
activators. Commonly referred to as "clot-busting drugs", plasminogen activators initiate 
a cascade of events that result in the dissolution of the occlusive clot and the 
recanalization of the blood vessel. In order to be effective, the infused dosage must be 
significant enough to overwhelm various components within the circulatory system (i.e. 
plasminogen activator inhibitors, antibodies, az-antiplasmin), as well as compensate for 
the agent's short half-life. As with any agent, the large requisite dosage translates into 
potential side effects such as uncontrolled hemorrhaging. In order to fully understand the 
motivation for encapsulation, some background on plasminogen activators is provided.
BACKGROUND ON PLASMINOGEN ACTIVATORS
The most often-utilized plasminogen activators are tissue-type plasminogen 
activator and its genetic variants (e.g. alteplase, retavase, tenecteplase, lanoteplase), 
streptokinase, urokinase, and staphylokinase [29]. Tissue-type plasminogen activator (t- 
PA) and its variants are direct activators, converting plasminogen to plasmin without the 
assistance of another molecule. Streptokinase and staphylokinase, on the other hand, are 
classified as indirect activators. These two proteins must first combine with 
plasminogen, a plasma protein, to form a 1:1 molar ratio activator-plasminogen complex, 
which then becomes the activator.
The streptokinase-plasminogen complex, like the plasminogen activators listed 
above, is a serine protease that has the ability to cleave the Arg^ao-Val^i peptide bond of 
plasminogen to form plasmin. Plasmin, in turn, degrades large proteins such as 
Sbrinogen and fibrin. The degradation of fibrin results in the breakdown of thrombi 
(Figure 2.1) and the restoration of blood flow to oxygen-deprived tissues. Derived from 
streptococcal cultures, streptokinase is one of the smaller plasminogen activators with a 
molecular weight of 47 kDa and is cleared rather quickly from plasma (approximately 16 
minutes by antibodies; 90 minutes by protein clearance). Owing to its lack of fibrin 
specificity, streptokinase activates circulating and clot-bound plasminogen 
indiscriminately. Fibrin specihcity can be defined as the preference of a plasminogen 
activator to activate fibrin-bound plasminogen (such as with tPA) over circulating 
plasminogen. Reduced fibrin specificity has been implicated as a cause of potential 
bleeding complications. Plasmin formed in circulating blood is rapidly neutralized by a%- 
antiplasmin (-X).l s) and is therefore unavailable for clot lysis [8]. Plasmin that remains
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Figure 2.1: Mechanism of fibrin degradation with plasminogen activators [adapted from 29]
after the inhibitor is exhausted can degrade other plasma proteins such as fibrinogen, 
which can result in hemorrhaging. Plasminogen activators are known to deplete the 
concentration of multiple plasma proteins over the course of their existence [14,15]. Use 
of streptokinase or staphylokinase also initiates the formation of antibodies due to their 
derivation 6om bacterial cultures. When infused, the anti-streptokinase titer rises to 
nearly 100 times the preinfusion level and has been reported to sustain such elevation for 
months or even years [30].
The transport of plasminogen activators into the thrombus has been shown both 
experimentally and analytically to play a significant role in clot digestion [31]. Magnetic 
resonance imaging studies by Blinc et al. [32,33], along with light microscopy studies by 
Diamond et al. [28, 34], have clearly shown the effect of convection in addition to 
diffusion alone of these agents. While transport of the drugs by diffusion thoroughly and 
completely digests the thrombus, lysis is much slower than that observed in the 
physiological setting. In contrast, permeation of the thrombus by plasminogen activators 
digests the clot much more rapidly but incompletely compared to diffusion alone. 
Convection forces the plasminogen activator into the middle of the thrombus due to 
higher flow velocities in the center and is further encouraged by a reduced pressure drop 
over the length of the clot. Increased transport of the agent into the center results in 
residual thrombus on the vessel walls not observed with diffusion alone. Attempts have 
been made to analytically describe the phenomenon of clot lysis and explore the 
mechanisms of incomplete lysis [35, 36].
Efforts to improve upon plasminogen activators have focused primarily on two 
6"onts. The development of new agents is one obvious method. By varying the protein
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structure of current agents, new drugs can be developed that have improved 
characteristics such as longer half-life, increased fibrin-specificity, or more convenient 
infusion capabilities. Recombinant technology has allowed for the production of these 
proteins to become economically feasible. However, current cost estimates for drug 
development of new compounds are placed at more than $850 million over a 10-12 year 
period (Tufts Center for the Study of Drug Development, 2003). The risk and high cost 
of development limits the discovery and availability of new agents.
A second possibility for improvement of plasminogen activators is to consider the 
delivery of the agent to the clot. Intrathrombic delivery of plasminogen activators has 
been recently reviewed [37]. It was anticipated that delivery of the fibrinolytic agent 
directly to the clot would limit its interaction with plasma proteins, thereby promoting 
improved thrombolysis. However, the experimental benefit achieved did not merit the 
specialized personnel and equipment that would be required compared to an intravenous 
infusion of the same agent. Additionally, direct infusion of plasmin has been explored as 
a means to limit the difficulties observed due to the short half-lives of plasminogen 
activators. Intraaortic infusion of plasmin demonstrated benefit in a rabbit ear puncture 
re-bleed model by providing comparable thrombus digestion without hemorrhaging 
versus t-PA which resulted in bleeding in 9 of 10 animals [38]. Coincident use of 
ultrasound [39], concomitant administration of plasminogen [40,41] and pulse-spray 
thrombolysis [42] have each shown a potential for enhancing thrombolysis. Despite 
promising preliminary results, each method has drawbacks such as the requirement of 
specialized procedures or an increased potential to form an embolus from the macerated 
thrombotic occlusion.
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Chemical modification of plasminogen activators has been investigated as a 
means to improve thrombolysis without developing new pharmaceutical agents. 
"Pegylation" of proteins has proven an effective technique to extend their brief half-lives 
when administered intravenously. Dramatic improvements have been observed by 
covalently linking polyethylene glycol to insulin, interferons, interleukins, tumor necrosis 
factor, superoxide dismutase, and others [43]. In addition, t-PA [44], urokinase [45], and 
streptokinase [46] have each been pegylated. While extended circulation times were 
reported for each study, thrombolytic efficacy was not adequately explored.
Recently, targeted delivery of streptokinase has been attempted by means of 
linking an anti-fibrin antibody to inactivated thrombin, then coupling to a hirulog- 
streptokinase fusion protein possessing lytic activity [47]. Streptokinase is released upon 
the arrival of hirudin which separates the hirulog from the inactivated thrombin bound to 
the anti-fibrin antibody, and is now free to attack the components of the thrombus while 
sparing the circulating clotting factors. Similar studies have also been reported with 
urokinase [48]. This approach is designed to limit hemorrhaging but has yet to be 
reported as a successful thrombolytic complex in vivo.
Streptokinase is often underutilized because of its lack of fibrin specificity 
compared to agents such as t-PA. There is some evidence that the low affinity for fibrin 
contributes to the potential for bleeding. Recombinant modification has demonstrated the 
potential for improving the fibrin specificity of streptokinase [49]. Reed et al. removed 
the 59 amino-terminal residues on streptokinase to form a plasminogen activator that was 
fibrin specific and no longer capable of fibrin-independent plasminogen activation. The 
thrombolytic superiority of the mutant streptokinase was verified when comparing
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recombinant streptokinase containing the NH; residues by the digestion of plasma clots. 
At the end of a six-hour exposure to the thrombi, amino-deleted streptokinase digested 
approximately 80% of the thrombus compared to only 50% with the full recombinant 
streptokinase. In addition, fibrinogen levels remained much higher with the deletion-type 
streptokinase versus unmodified streptokinase (10% degradation versus 97%, 
respectively), suggesting the reduced potential for bleeding complications with this 
technique.
While chemical modification of currently used agents has shown potential, 
physical association of the drugs for delivery in acute crises has not received much 
attention. Despite the many avenues pursued to improve fibrinolysis, few studies have 
examined the efGcacy of encapsulating plasminogen activators in a vehicle. The vehicle 
should shield the protein for a period of time, thereby lessening the susceptibility of 
proteinaceous drugs to inhibition by circulating plasma proteins, premature activation, 
systemic removal by antibodies, or simple breakdown due to the body's harsh 
environment. While in the vehicle, active agents should remain unrecognizable to 
inhibitors, antibodies, and the environment. Encapsulation also could effectively increase 
the half-life of an agent by extending its circulation time in the body, as the short half-life 
plays a role in the reduction of total protein activity.
PREVIOUS USE OF ENCAPSULATION
Encapsulation of drugs is not a novel idea. In fact, many compounds have been 
encapsulated in a number of vehicles over the last three decades. Drugs are encapsulated
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for a variety of reasons, most commonly to provide a prolonged, steady release rate and 
to limit the side effects that can result hrom these agents [50].
Drugs can be administered in a variety of modes other than the conventional oral 
route. The delivery of an active agent has a profound effect on its potential benefits, such 
as improved patient compliance and decreased dosage. For example, drugs utilized for 
chemotherapy have been trapped in polymer wafers and then implanted in the brain as a 
fbllow-up to surgical tumor removal [50]. By placing the wafers at the site of tumor 
removal, a reduction in total dosage of the chemotherapy agents is possible, thereby 
resulting in fewer side effects.
In contrast to controlled delivery's conventional goal of steady, sustained 
administration, this study is focused on the use of encapsulation to improve the properties 
of plasminogen activators. Tissue begins to suffer almost immediately following oxygen 
deprivation, and therefore, restoration of flow must be achieved quickly. New delivery 
methods of clot-busting drugs should be considered in order to better the survival rate of 
victims and improve upon the drawbacks of plasminogen activators.
As mentioned previously, encapsulation of thrombolytic agents has demonstrated 
dramatic improvements over free plasminogen activators by reducing the time required to 
digest a clot as well as increase the percentage of the clot that is digested (Table 2.1). 
Early studies at the University of Oklahoma were the first to report accelerated 
thrombolysis in vivo using an encapsulated plasminogen activator [22]. Multiple agents 
have shown benefits using two animal models [22-25]. Each study pertaining to 
liposomal encapsulated agents has proposed various hypotheses to explain how
15
Reperfusion
Time
(min)
Reperfusion
Time
(min)
Percent
lysis
(%)
Percent 
lysis 
(%) _
Animal model canine canine rabbit rabbit
Agent streptokinase urokinase streptokinase t-PA
Free agent 78 ±43 69 ±7 36.3 ±3.4 26.3 ±3.8
Encapsulated
agent
32 ±28 28 ±7 47.4 ± 1.4 34.8 ±3.6
Reference 22 23 24 25
Table 2.1: Previous in vivo studies utilizing liposomal encapsulated plasminogen 
activators (mean ± standard deviation).
encapsulation promotes thrombolysis. Nguyen et al. suggested that the liposomes rupture 
due to the shear stress on the vesicles that occurs when they arrive at and begin to pass 
the clot [22]. The liposomes then release their payload and lysis begins. Frezard states 
that "fluid" liposomes, such as those made from dioleoylphosphatidylcholine in the study 
of Nguyen et al., disintegrate and release their contents within a few minutes after their 
intravenous administration [51]. This is due in large part to the transference of the lipid 
molecule from the liposomal membrane to plasma high density lipoproteins. It is also 
likely that the liposomes protect the enzyme &om components in the plasma that cause 
degradation or premature activation. Another study has shown that plasminogen binds to 
the surface of the liposome, leading the investigators to suggest that plasminogen acts as 
a "homing device" for the clot [52]. The plasminogen would then reduce the free 
circulation of the liposome and attract the encapsulated thrombolytic agent to the clot.
Encapsulation of streptokinase in liposomes has been shown to significantly 
prolong the systemic delivery of this agent [53]. Liposomes composed of
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distearoylphosphatidylcholine and polyethylene glycol (PEG) increased the half-life and 
average systemic concentration by 16.3- and 6.1-fold, respectively, compared to 
streptokinase alone. However, it is not clear if increases in circulation times are due to 
the liposomes themselves or the addition of PEG to the liposomal membranes. As will be 
discussed in the next chapter, PEG resists plasma protein adsorption that would likely 
limit opsonization and removal from the circulation by the reticuloendothelial system. 
PEG has been successfully added to other liposomes to demonstrate extended circulation 
times [54].
Despite the clear enhancement of fibrinolysis achieved with liposomal 
encapsulation, liposomes are known to have limited stability in the aqueous state [22,55], 
severely limiting the commercial potential of this system. While progress towards 
improved stability and encapsulation efficiency using liposomes has been reported [56, 
57], other vehicles should be investigated. Therefore, efforts in our laboratory are 
underway to develop a second-generation vehicle which maintains the benefits observed 
with liposomal encapsulated thrombolytic formulations and yet avoids the limited 
stability observed with vesicles. A solid dosage form would be desirable in order to 
optimize and control shelf life. The development of a polymeric encapsulated 
thrombolytic formulation has been explored and is described in the forthcoming chapters.
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ASSESSING THE POTENTIAL EFFICACY OF 
ENCAPSULATED STREPTOKINASE IN A 
RABBIT MODEL OF CAROTID ARTERY THROMBOSIS
CHAPTER]
TTzM cAapfgr Aay m large parf/or /;a6/zcaf;0M.
INTRODUCTION
Despite the success achieved with intravenously administered thrombolytic 
agents, plasminogen activators suHer &om several limitations that hamper systemic 
administration. As discussed in Chapter 2, encapsulation has been examined in various 
models as a means to enhance thrombolysis. Although the direct mechanism for 
improved lysis with liposomal encapsulated agents has only been theorized, the general 
consensus is that encapsulation would protect the drug 6om premature removal/ 
deactivation by components of the circulation such as antibodies and PAI-1. Protection 
&om premature degradation would effectively extend the agent's half-life and allow for a 
greater drug dosage to initiate clot digestion. Canine coronary and rabbit jugular models 
of thrombosis have been successfully implemented to demonstrate the enhanced 
thrombolytic capability of liposomal encapsulated plasminogen activators compared to 
identical dosages of free activator. However, the potential of these formulations to treat
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cerebral ischemia has not been examined. To that end, a rabbit model of carotid 
thrombosis has been implemented as an approximation of stroke to explore the potential 
efGcacy of encapsulated streptokinase for treatment of cerebral ischemia.
Liposome preparation by most techniques is a lengthy process (approximately 4-7 
days), and these vehicles lack stability in their aqueous form for periods greater than 48 
hours [22, 55]. Depending on particle size, a large percentage of vesicles are susceptible 
to the first-pass phenomenon in which they are cleared from the circulation by 
components of the reticuloendothelial system (RES) such as the liver, spleen, and bone 
marrow following opsonization by plasma proteins [58, 59]. These difficulties have 
reduced commercial appeal for these agents despite the accumulating evidence for their 
efficacy. Therefore, we have sought to develop a formulation of encapsulated 
streptokinase that demonstrates comparable beneGt to that observed with liposomal 
encapsulated streptokinase but with improved storage potential, which would likely 
translate into improved commercial viability.
Although there are several techniques to prepare liposomes including the freeze- 
thaw and extrusion methods, the detergent removal method is a popular and reproducible 
approach [51, 60, 61]. Liposomes are prepared by taking advantage of differences in 
hydrophobicity with various components. Vesicles are formed from phospholipids that 
are composed of a long chain hydrophobic fatty acid and a hydrophilic polar head group. 
When placed in an aqueous environment, a bilayer is formed as the hydrophobic tails 
arrange themselves to be in close proximity, while the hydrophilic heads point toward the 
aqueous environment (Figure 3.1). In this manner, dissolved proteins such as 
streptokinase can be entrapped within the confines of the phospholipid bilayer, oftentimes
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Figure 3.1: Schematic of liposome
resulting in spherical vesicles. For the detergent removal method, lipids are first 
solubilized with an aqueous solution of the detergent that also contains the protein(s) to 
be encapsulated. The detergent must have a high critical micelle concentration (CMC) so 
that it is easily removed, for instance by dialysis.
The fatty acids that make up the phospholipid bilayer are susceptible to oxidation 
after approximately 48 hours [26, 51], thereby compromising the bilayer's continuity and 
allowing the unpredictable release of the entrapped agent. This severely limits the ability 
to adequately assess the amount of encapsulated agent at times past 48 hours. For a 
liposomal encapsulated thrombolytic formulation to be usable in a widespread manner, 
clinicians would have to predict the need for such a formulation as anything that was 
prepared more than 48 hours previously would likely need to be discarded. The 
tremendous amount of wasted drug that would result 6om this scenario has certainly 
dampened the movement of such technology to the clinics.
Other vehicles or formulation processes must be considered to address this issue. 
While other laboratories are focusing on methods to improve encapsulation efficiency 
and storage characteristics of the liposomal formulations [56, 57], we have considered the 
use of other materials and processes to entrap streptokinase. Polymeric formulations 
would seem to be ideal for this application with their ability to be lyophilized into a dry 
powder, thereby providing extended storage possibilities compared to aqueous liposomal 
formulations.
Microencapsulation of proteins has been pursued for a number of years with 
significant success when entrapping various proteins such as insulin, superoxide 
dismutase, and even cellular material such as islet cells [62-64]. Traditional techniques
2 1
for microencapsulation seek to extend the release of the entrapped material for extended 
periods as in weeks to months. While there are a number of techniques to encapsulate 
proteins in microparticles, the double emulsion technique is a relatively simple method 
that has been successful for a number of proteins. Additionally, this formulation process 
affords many preparation steps that can be modified in order to affect particle diameter, 
size distribution, release rate, and porosity [65].
Release rate can be affected by a number of factors including the polymer 
molecular weight, the presence of cross-linking molecules, porosity, and particle size 
[65]. Increasing the molecular weight will prolong the degradation of the polymer, as 
will the presence of crosslinking moieties such as dialdehydes [66, 67]. Particles with 
greater porosity provide more channels for the invasion of fluid which promotes the 
degradation of water-soluble material. Lastly, smaller particles dissolve faster than larger 
particles as microparticulate degradation is dependent on the ratio of surface area to 
volume.
When selecting a vehicle for a specific application, one must first look at the 
requisite properties of the desired medium. For this particular application, it is desired to 
make use of a polymer that has a reasonable shelf life (> 3 months). Restrictions 
common to all biomaterials apply; it should be water-soluble, biodegradable, 
biocompatible, nontoxic, as well as dissolve rather quickly. After some preliminary 
investigation, microparticles were formed of polyethylene glycol with molecular weights 
of 10,000 (rabbit studies) and 20,000 (in vitro and canine studies).
Polyethylene glycol (PEG) has been shown to have a number of interesting 
properties that could result in potential benefits for this application [68]. Firstly, the
2 2
polymer has a high solubility in water that results in a short dissolving time. It is unusual 
in the group of water-soluble polymers in that it is soluble in a variety of organic solvents 
as well such as chloroform, methylene chloride and ethanol. The immobilization of PEG 
to other polymer surfaces greatly reduces protein adhesion. Lastly, covalent coupling of 
PEG to proteins decreases their immunogenicity and increases their half-life in plasma 
[69].
For the application of encapsulating streptokinase in a microparticulate system, 
the goal is not to delay release of the drug for long periods of time, but to delay the 
release for only enough time to allow the particles to reach the thrombus. As PEG offers 
a number of advantages for a polymeric material in contact with blood, the feasibility of 
microencapsulated streptokinase formed of PEG has been explored and directly 
compared to identical dosages of free and liposomal encapsulated streptokinase using a 
rabbit model of carotid thrombosis [70].
MATERIALS AND METHODS 
Preparation of LESK
Unilamellar phospholipid vesicles were prepared through the detergent removal 
method [22, 26]. Vesicles were prepared in the Department of Medical Biochemistry and 
Genetics at Texas A&M University, College Station, TX. Briefly, POPC (160 mg; 1- 
palmitoyl-2-oleoyl-sn-glycero-3-phosphotidylcholine; Avanti Polar-Lipids) was dried 
under vacuum using a centrifugal evaporator, together with 0.1 pCi of l,2-di[l-'^C]- 
oleoyl-L-3-phosphatidylcholine (Amersham Life Science) added for tracing purposes, 
and then resuspended in 2 mL of 1 mol/L OG (n-octyl-P-D-gluco-pyranoside; Sigma
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Chemical) ih HBS [HBS:50 mmol/L HEPES (pH 7.5), 100 mmol/L NaCl] at 37°C for 2 
hr with occasional mixing.
SK (80,000 lU; Behringwerke AG) was dissolved in the resuspended POPC, and 
then OG was removed by dialysis against 4 L of HBS (6 changes, 12 hours/change) at 
4°C. The resulting LESK was purified &om unencapsulated SK by gel filtration in HBS 
at 4°C through a Sepharose CL-6B column (7 mm i.d. x 500 mm). LESK eluted in the 
void volume, as evidenced by the coincident detection of protein by absorbance at 280 
nm and of phospholipid by radioactivity in the 1.2-mL fractions. Particle sizes averaged 
339 ±154 nm in diameter as determined by a NIDEC 270 Submicron Particle Sizer. The 
preparation process required 4 days, and the vesicles were shipped by overnight express 
mail for use the next day in the Animal Resources facility at the University of Oklahoma 
Health Sciences Center, Oklahoma City, OK.
Preparation of MESK
SK was entrapped in microparticles through a modified double emulsion method 
as illustrated in Figure 3.2 [62, 71]. PEG (1 gm of 10,000 MW, Sigma Chemical) was 
dissolved at room temperature in 1.3 mL chloroform (Fisher Scientific) and SK (40,000 
lU; Behringwerke AG) was dissolved separately in 250 pL of distilled water, also at 
room temperature. The two solutions were mixed and sonicated for 45 s at 40-50 watts 
(Sonic Dismembrator 550, Fisher Scientific). SK activity was not altered by sonication at 
this intensity and duration. The protein/polymer solution was mixed with 1 mL of 2% 
(w/v) polyvinyl alcohol (PVA; average MW 30,000-70,000; Sigma Chemical) and 
vortexed for 20 s. A small volume (250 pi) of 25% (w/v) glutaraldehyde (Electron
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Figure 3.2: Schematic of modified double emulsion method.
Microscopy Sciences) was added to promote crosslinking and extend particle dissolution 
time, a technique used to slow release rates from both polymer [66,67] and protein [72] 
microparticles. SK activity was not significantly influenced by this concentration of 
glutaraldehyde. The mixture was vortexed 20 s, and then placed in a -85°C 6eezer for 20 
minutes. The mixture was lyophilized for at least 15 hours. After the water was 
extracted, the mixture was washed in hexane three times in a centrifuge at 1000 x g  and 
4°C for 5 min each and filtered under a vacuum in order to remove any externally bound 
protein. Final product composed of porous, mostly spherical particles with a number- 
averaged diameter of 810 ± 523 nm (mean ± SD; 90% < 1287 nm) was then stored at 
room temperature until use. An image of a representative microparticle is captured by 
scanning electron microscopy in Figure 3.3. Blank microparticles lacking entrapped SK 
were prepared by replacing the SK solution with an identical volume of distilled water 
and carrying out the preparation process as previously described.
Encapsulation Efficiency
SK content in the pooled LESK peak fractions was quantified with a 
commercially available chromogenic activity assay (Helena Laboratories) both in the 
presence and absence of OG (100 mmol/L final concentration) [22]. Octylglucoside was 
used to rupture the vesicles for quantitative determination of the encapsulated product. 
The activity of the released plasminogen activator from LESK after rupture was 
compared to standard curves of SK prepared in identical concentrations of 
octylglucoside.
SK content of the microparticles was quantified with the same activity assay. The
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4Figure 3.3: Scanning electron micrograph of a microparticle of encapsulated
streptokinase as prepared with the modified double-emulsion technique.
microparticles were allowed to dissolve completely in distilled water for approximately 
45 min. This process can be followed and confirmed by light scattering studies using a 
Coulter LS Particle Size Analyzer (Beckman Coulter). The activity of each sample was 
compared to that of a standard curve of SK in the presence of an identical concentration 
of completely dissolved blank microparticles.
Animal Model
Animals were treated under procediues that were examined and approved by the 
Institutional Animal Care and Use Committee of the University of Oklahoma Health 
Sciences Center, as well as the University of Oklahoma. The present study examined the
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performance of four thrombolytic formulations (FREE SK, FREE SK + BLANK, LESK, 
and MESK) in vivo through the use of a rabbit model of carotid artery thrombosis [73] 
which was modified in our laboratory. New Zealand white rabbits of either sex weighing 
an average of 2.65 kg were anesthetized (5%) and maintained (2-3%) with inhaled 
isoflurane. Cardiac activity was monitored by ECG. The right carotid artery was 
isolated, as was the left jugular vein. The jugular vein was cannulated with PE-90 tubing, 
which was coimected to a 20-mL syringe for administration of study formulations. Right 
carotid artery flow was followed with a 20-MHz pulsed Doppler probe cuff placed in 
direct contact with the vessel, a technique that measures the velocity of red blood cells 
passing through the artery. Autologous whole blood (0.1 ml) was withdrawn slowly over 
10 s from the carotid artery into a glass syringe containing approximately 100 units 
thrombin (Sigma Chemical) before reinjection into a 5-10 mm long ensnared segment of 
proximal and distal right carotid artery. After 10 min, the proximal ligature was released, 
as was the distal ligature after an additional 5 min. Most vessels occluded with one or 
two thrombin injections. The thrombus was allowed to mature for 30 min prior to 
administration of any study formulation.
The relative dosages of the thrombolytic preparations were identical. A dosage of 
6,000 lU/kg was determined as adequate to produce thrombolysis. The preparation was 
dispersed in normal saline to a total volume of 20 mL. An initial bolus of 20% preceded 
a constant intravenous infusion of the remaining formulation over a 30 min period. As a 
control, empty microparticles (1.5 gm) were mixed with 6,000 lU/kg of free streptokinase 
(FREE SK + BLANK; n=3) and administered via the jugular vein. Animals were 
observed for 2 h following the initiation of infusion. Reperfusion was documented by a
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Figure 3.4: A rabbit model of carotid thrombosis was used to test thrombolytic efficacy 
of various free and encapsulated formulations of streptokinase.
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recovery of right carotid arterial flow. Sustained reperfusion was defined as flow 
returning to at least 20% of the pre-thrombosis baseline flow for the remainder of the 
experiment without another occlusion event. At the conclusion of the experiment, the 
artery was dissected and residual thrombus mass determined gravimetrically.
STATISTICS
Using a nonparametric analysis of variance followed by an unpaired t-Test, p 
values < 0.05 were considered significant. Unless otherwise stated, all results are 
expressed as mean ± standard error of the mean.
RESULTS
Encapsulation EfGciency
The ability to encapsulate SK in a liposome varies greatly with the conditions of 
encapsulation and the method used. By employing the detergent removal method, an 
average of 30% of the initial SK was entrapped within the vesicles (150 lU SK/ mg of 
phospholipid). This incorporation rate compares well with other studies utilizing assorted 
techniques for liposomal entrapment of various plasminogen activators [22-26].
As with liposomal encapsulation, the efficiency of protein microencapsulation 
varies greatly with the reagents used, the conditions during preparation, and the 
techniques employed. At the conclusion of preparation, final product yield for the 
production of MESK (PEG + SK 4- PVA) was 82.0 ± 2.2% (n=7) by weight, while the 
encapsulation efficiency of viable SK was 29.0 ± 3.2% (11.1 ± 0.86 lU/ mg of PEG). On 
average, 1.47 ± 0.08 gm of MESK was infused for each rabbit.
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Animal Model
The thrombolytic activity of LESK and of MESK was directly compared with 
FREE SK. The average time required for reperfusion with FREE SK (n=6) was 74.5 ± 
16.9 min (Figure 3.4). Two animals treated with FREE SK did not achieve reperfusion 
and were given values of 121 min for the sake of statistics. In sharp contrast to FREE SK 
values, LESK (n=7) greatly reduced thrombolysis times to 19.3 ± 4.6 min (p = 0.006 vs. 
FREE SK), with one reperfusion observed as quickly as 8 minutes. MESK (n=6) reduced 
the time to restore blood flow even further to 7.3 ± 1.6 min (p = 0.003 vs. FREE SK). 
Admixing of FREE SK and blank microparticles (FREE SK + BLANK) resulted in 
comparable reperfusion times (54.7 ± 3.9 min; p>0.05; ns) to those FREE SK animals 
which reperfused (51.3 + 10.6 min). As expected, an equal volume of saline alone (n=4) 
failed to result in reperfusion of the occluded carotid artery. A trend of decreasing 
residual clot mass can be observed with decreasing reperfusion time for each 
encapsulated formulation (Figure 3.4). Substantial differences in clot mass can be 
observed with both encapsulated formulations as compared to FREE SK alone. FREE 
SK + BLANK demonstrated similar clot masses to FREE SK alone.
In addition to the dramatic reduction in the time required to achieve reperfusion 
when utilizing both encapsulated streptokinase formulations, we also observed an 
increase in the percentage of baseline flow that was returned with LESK and MESK 
(Figure 3.6). Flow through the occluded carotid artery was monitored through the use of 
a 20-MHz pulsed Doppler flow probe. Baseline flows were determined prior to irgection 
of thrombin, and readings were collected at various time points throughout the 
experiment. Determination of the percentage of returned blood flow was calculated by
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taking the ratio of the mean flow velocity at specified time points to the pre-thrombosis 
mean flow velocity. The best-fit lines through the data points are generated vyith a one- 
phase exponential model (FREE SK R  ^= 0.952; LESK R  ^= 0.972, MESK R  ^= 0.969).
As seen in Figure 3.5, a greater percentage of original baseline flow is returned 
earlier with both encapsulated formulations than with FREE SK. MESK seems to reach 
its optimum return of flow at approximately 30 minutes; the flow remains constant for 
MESK until the end of the experiment, while LESK and FREE SK exhibit a gradual 
increase in flow throughout this time period. At the conclusion of the experiment, both 
LESK and MESK resulted in a return of flow noticeably higher than that obtained with 
FREE SK. The substantial increase in end flow shows that encapsulation has a profound 
effect on the level of blood flow restoration, as well as on the time course of restoration.
For experiments in which encapsulated formulations were administered, an 
absence of reocclusion was documented. It is not uncommon to observe episodes of 
reocclusion following reperfusion with streptokinase. The mechanism of reocclusion is 
unknown but possible causes include thrombi traveling downstream, the release of 
various chemicals that cause restenosis due to spasm of the blood vessel, or the exposure 
of active surfaces that initiate platelet response. In rabbits treated with FREE SK, an 
average of 1.0 ± 0.69 reocclusion events occurred per rabbit within 2 h after initiation of 
treatment. Incidences of reocclusion were reduced with both encapsulated formulations, 
with LESK averaging 0.71 ± 0.29 events and MESK averaging 0.33 ± 0.21 episodes 
(p=ns vs. LESK or FREE SK) per rabbit. Occlusions treated with LESK and MESK 
tended to remain open after initial reperfusion, while the use of FREE SK was often
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accompanied by multiple episodes of reocclusion and subsequent reperfusion. The 
infusion of FREE SK + BLANK resulted in 0.33 ± 0.24 reocclusions per animal.
Streptokinase administered intravenously is known to invoke a systemic lytic 
state. More specifically, the hemostatic plugs that seal preexisting sites of vascular injury 
are susceptible to clot lysis like the larger, occlusive blood clot. Streptokinase is also 
known to degrade the concentration of circulating fibrinogen, a plasma protein necessary 
for normal blood clotting processes [15,16]. In animals receiving FREE SK, extensive 
bleeding &om the injury sites was qualitatively observed compared to those animals 
receiving either LESK or MESK. Substantial bleeding was routinely observed from the 
thrombin injection site of the carotid artery, as well as the surgical incisions with rabbits 
receiving free streptokinase, while such bleeding was not evident in rabbits receiving the 
encapsulated formulations for treatment of thrombosis.
DISCUSSION
For victims of cardiovascular crises, it is imperative to receive treatment as soon 
as possible. Studies involving myocardium in dogs have shown that infarct mass 
increases with the duration of coronary artery occlusion preceding reperfusion [74]. 
Human clinical studies have shown that a treatment delay of only 43 minutes results in a 
larger infiarct size and reduced left ventricular function [75-77]. Therefore, the prognosis 
for patients improves dramatically when achieving reperfusion soon after symptoms 
occur.
This study is directed towards reducing the time necessary to restore the flow of 
blood to the tissue once treatment is initiated. As illustrated in Figure 3.5, the infusion of
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LESK and MESK resulted in significantly faster reperfusion times than were observed 
with FREE SK. In addition to the reduced time required to restore blood flow through 
the occluded vessel, a greater percentage of the flow was returned more rapidly with both 
encapsulated formulations than with FREE SK, with MESK reaching a maximum level 
of flow one hour faster than LESK (Figure 3.6). The faster reperfusion times and 
reduced residual clot sizes observed in this model likely result from a reduction in 
reocclusion episodes during treatment with LESK and MESK. It would be reasonable to 
assume that reocclusion is limited in the latter cases by the increased rate and extent of 
clot lysis observed with the encapsulated formulations when compared to free 
streptokinase.
One theory for the efficacy of encapsulation in thrombolysis is the blocking of 
channeling by the particles and a subsequent increase in pressure at the leading edge. 
Heeremans et al. compared the thrombolytic ability of free t-PA to free t-PA + empty 
liposomes in a rabbit jugular vein model [24 ] .  Freely infused t-PA resulted in a similar 
degree of clot lysis as that obtained with an identical dosage of t-PA + empty liposomes 
(26.3% vs. 21%; p>0.05; ns). Perkins and coworkers also observed no statistical benefit 
with FREE SK + empty liposomes [25]. Due to this small difference in the percentage of 
lysed clot, it is unlikely that an increase in pressure due to the blocking of chaimeling 
plays a sizable role in the lysis of clots with encapsulated formulations. In this model, 
FREE SK + BLANK resulted in no significant improvement over FREE SK. Similar 
results have been obtained in our laboratory in vivo using FREE SK + empty liposomes 
or microparticles. Clearly, the true benefit is only observed when the plasminogen 
activator is closely associated with the vehicle.
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The mechanism of action by MESK will be addressed in detail in Chapter 5 in 
which a number of in vitro experiments are discussed. In brief, streptokinase is protected 
from circulating plasma proteins by sequestration within the microparticles. Perhaps 
more importantly, encapsulation of streptokinase within the microparticles facilitates clot 
permeation Wiereas &ee streptokinase binds to the surface due to reactions with plasma 
proteins. Improved permeation of the thrombus leads to greater distribution of 
streptokinase within the thrombus as the particles dissolve.
In this study, SK was encapsulated in microparticles formed of PEG. Mammalian 
enzymes are unable to breakdown the polyether backbone of PEG, leaving the degraded 
material to be filtered from the blood compartment by the kidneys [69]. In vitro 
experiments in our laboratory have demonstrated the time-dependent microparticle 
dissolution and release of fluorescently-labeled SK 6"om MESK in plasma (data not 
shown). Over the 120 min period of this experiment, the Tyndall effect can be observed 
during the solubilization of microparticles along with the release of a green dye.
Based on these preliminary results, microencapsulation of thrombolytic drugs 
offers a promising alternative for current products used to treat thrombosis with the 
potential to salvage more tissue and reduce bleeding complications. Further experiments 
were undertaken to explore the mechanism of encapsulated streptokinase's action as well 
as examine its potential in a model of greater clinical efficacy. This work will be 
explained in Chapters 4 and 5, respectively.
37
ASSESSING THE POTENTIAL EFFICACY OF ENCAPSULATED 
STREPTOKINASE IN VITRO IN ORDER TO EXPLORE ITS 
MECHANISM OF ACTION
CHAPTER 4
INTRODUCTION
Significant differences in thrombolytic ability have been observed between &ee 
and encapsulated streptokinase in a rabbit model of arterial thrombosis. In order to 
explore the mechanism utilized by microencapsulated streptokinase to digest thrombi 
more rapidly than free streptokinase, an in vitro system was used so as a number of 
variables could be easily controlled (i.e. clot age, clot structure, pressure drop, etc.). The 
system allows for changes in clot type to investigate the effect of clot retraction, as well 
as variances in applied pressure.
As previously shown by Diamond, Blinc, and others, thrombolysis is a pressure- 
mediated phenomenon [31-36]. With diffusion as the sole mode of plasminogen 
activator transport within the clot, drugs would move only millimeters over hundreds of 
minutes. Clearly, diffusion is not the dominant transport mechanism. Convection, or
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forced movement, is the prevailing method of transport within the thrombus. Interstitial 
flow of plasma through a thrombus can be adequately described by Darcy's law of flow 
through porous media:
= (4.1)
where v is the interstitial fluid velocity, Q is the flowrate, vf is the cross-sectional area 
available for fluid passage, A is the permeability of the media, is the fluid viscosity, and 
Æ*/2 is the pressure drop across the media. It is apparent that increases in pressure drop 
over the length of the clot should result in faster lysis due to faster inflow of plasminogen 
activator. Such increases arise when the length of the clot is reduced due to clot 
digestion. Previous in vitro studies used low pressure drops much like that observed in 
the case of venous thrombosis [28]. Higher pressure drops are required to better 
approximate the coronary thrombotic condition in which pressure drops can reach 60 
mmHg/cm-clot.
To that end, the thrombolytic potential of MESK has been investigated using a 
simple in vitro system with two clot types (plasma and whole blood) and at three 
increasing initial pressure drops per clot type. Initial pressure drops utilized for plasma 
clots were 5, 10, and 15 mmHg/cm-clot, while whole blood clots were exposed to initial 
pressure drops of 10, 20, and 30 mmHg/cm-clot. Although these values are still 
significantly smaller than those that occur across arterial clots in vivo, these experiments 
are a better approximation of physiological conditions compared to previous studies.
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MATERIALS AND METHODS
Preparation of microencapsulated streptokinase (MESK)
Streptokinase was entrapped in a water-soluble polymer through a modified 
double emulsion technique [70, 71]. Briefly, 2 g of polyethylene glycol (20,000 MW; 
Polysciences, Inc., Warrington, PA) was dissolved at room temperature in 3 ml 
chloroform (Fisher Scientific, Pittsburgh, PA) and streptokinase (Streptase®, 40,000 lU, 
Behringwerke AG, Marburg, Germany) was dissolved separately in 0.2 ml distilled 
water, also at room temperature. The aqueous protein solution was added to the polymer 
solution and immediately dispersed by sonication (Sonic Dismembrator 550, Fisher 
Scientific, Pittsburgh, PA) at 10 W for 1 min to form the first emulsion. Sonication for 
this length of time did not significantly alter the activity of streptokinase. The 
protein/polymer solution was mixed with 8 ml of a 2% (w/v) polyvinyl alcohol solution 
(average MW 30,000-70,000, Sigma Chemical, S t Louis, MO) and vortexed for 20 s. 
The mixture was placed in a freezer at -80°C for 2 h and lyophilized for 15-20 h. The 
lyophilized product was washed with hexane in a centrifuge at 600 x g  for 10 min at 4°C, 
and then hltered under vacuum through 0.45 /an membranes to remove any protein 
bound to the external surface. The product was allowed to dry in a fume hood for 1 h. 
Final product (MESK) composed of porous, primarily spherical-shaped particles of 0.793 
± 0.026 /an average diameter (mean ± SEM) was then stored at room temperature until 
use. Blank polymer was prepared by replacing the streptokinase solution with an 
identical volume of distilled water. The remainder of the preparation was carried out 
following the same protocol as MESK. Microparticulate formulations with higher
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concentrations of encapsulated streptokinase per particle were prepared by initially 
adding greater concentrations of streptokinase (250,000 lU in 0.4 ml) prior to sonication.
Fluorescent labeling of streptokinase
Streptokinase was labeled with a commercially available fluorescent marker 
(Alexa Fluor 488, Molecular Probes, Eugene, OR) using the accompanying protocol at 
room temperature. Briefly, 6 mg (60,000 lU) of streptokinase was dissolved in 1 ml 
PBS. A small volume of 1 M sodium bicarbonate solution (50 pi) was added to 0.5 ml of 
the streptokinase solution to raise the pH for optimum label attachment. The protein 
solution was added to a vial of the reactive dye and stirred for 1 h. Unattached dye 
molecules were separated h-om the protein-dye conjugate by filtration through the 
accompanying column. Labeled streptokinase was collected and either used immediately 
in its free form, encapsulated, or frozen in small aliquots at -80°C until use. Fluorescent 
labeling of streptokinase did not significantly affect the agent's activity.
Preparation of whole blood and plasma clots
Clots formed of whole blood or plasma were prepared as described [28]. Human 
fibrinogen (Grade L; American Diagnostica, Greenwich, CT) was dissolved in 0.05 M 
Tris-HCl, pH 7.4 and dialyzed against 0.05 M Tris-HCl with 0.1 M NaCl and 5 mM 
CaCl2, pH 7.4 for 18 h with changes every 6 h and frozen in small aliquots at -80°C until 
use. Thrombin &om human plasma ( -  3000 NIH units/vial; Sigma Chemical, St. Louis, 
MO) was dissolved in Nanopure distilled water to a concentration of 2 NIH units/ml and 
frozen in small aliquots at -80°C until ready for use.
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Glass Natelson blood capillary tubes (Fisher Scientific) were prepared for clot 
formation by coating the interior surface with a thin layer of fibrin as described 
previously [78]. Briefly, the tubes were etched in a dilute solution of hydrofluoric acid 
(Fisher Chemical, Fair Lawn, NJ) for approximately 20 min, washed thoroughly in 
distilled water, and baked 1 h at 100°C. The tubes were allowed to cool to room 
temperature. The interior surface of the etched capillary tubes was coated with a fibrin 
solution to enhance adherence of the clots to the surface. A 1:1 mixture of fibrinogen and 
thrombin was rapidly mixed and injected into the etched tubes. The mixture was allowed 
to form a fibrin gel for at least 1 h at 37°C. After fibrin formation, the gel was gently 
removed with low air pressure, leaving a residual layer of fibrin deposited on the wall of 
the tube. The tubes were stored overnight at room temperature before use.
Whole blood was collected from healthy donors and anticoagulated with 0.13 M 
sodium citrate (1 volume part of sodium citrate per 9 volume parts of blood). Platelet- 
rich (PRP) and platelet-poor plasma (PPP) were obtained by centrifugation at 150 x g for 
10 min and 4600 x g  for 20 min, respectively. Platelet counts for PRP and PPP were 
significantly different (2.8e6 ±  1.4e5 platelets/ml and 1.5e5 ± 1.1 eS platelets/ml, 
respectively) as determined using a hemacytometer.
Clots of either whole blood or plasma were prepared in primed capillary tubes. 
Whole blood clots were formed by the addition of 0.25 M CaCL at a ratio of 8 pi 
CaClzilOO pi whole blood. A small volume ( -  80 pi) of freshly calcified whole blood 
was injected into a capillary tube to form a clot of approximately 3 cm in length. Clots 
were allowed to solidify for 2 h at 37°C. Plasma clots were formed by ii^ecting small 
volumes of a mixture of 50 pi PRP, 50 pi PPP, 100 pi thrombin, and 16 pi of 0.25 M
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CaClz and allowed to gel for 1 h at 37°C. Final thrombin concentration was 1 NIH 
unit/ml of plasma. Clots that formed with visible structural deformities such as interior 
void volumes or incomplete adherence to the tube wall were excluded &om the study. 
Following clot formation, the capillary tubes were connected to Tygon tubing and a 5 ml 
glass pipette (as a flowmeter) filled with a solution of 5 ml normal saline, 2 ml PPP, and 
the fibrinolytic study formulation (Figure 4.1).
Fibrinolysis of whole blood and plasma clots by 2500 lU streptokinase was 
investigated in vitro at room temperature. Study formulations included free streptokinase 
(FREE SK), microencapsulated streptokinase (MESK; approximately 150 mg), &ee 
streptokinase + polymer (FREE SK + BLANK), and a high concentration of encapsulated 
streptokinase per particle (HI MESK; approximately 50 mg). Pressure was applied by the 
addition of air monitored by a pressure gauge. Lysis of plasma clots was studied at initial 
pressure drops of 5, 10, and 15 mmHg/cm-clot. The applied pressure was kept constant 
throughout the experiment. Whole blood clots were examined at initial pressure drops of 
10, 20, and 30 mmHg/cm-clot, also keeping the applied pressure constant. The time 
required to dissolve the clot was monitored, along with the flow rate of perfusing 
formulation and the length of the clot at numerous time points.
Preparation of clots for confocal microscopy studies
Plasma clots were prepared for examination with confocal microscopy in a similar 
manner to that described above. Fibrinogen labeled with Alexa Fluor 594 marker 
(Molecular Probes, Eugene, OR) was dissolved in 1 M sodium bicarbonate solution at a
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Pipette used as a 
flowmeter to be filled 
with study formulation
Tubing filled 
with study 
formulation 
[2500 lU SK]
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air to vary pressure 
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Collection dish
Figure 4.1: In vitro ^paratus for examining clot digestion. Two clot types are utilized, and the initial
pressure drop across the clot is varied by adding air pressure or changing the length of the tubing.
concentration of 1.5 mg/ml. Rectangular glass capillary tubes were prepared for clot 
formation by etching and coating in an identical manner as described above. To form 
plasma clots, 100 pi PRP was mixed with 12 pi of labeled FBG, 15 pi of 0.25 M CaCl2, 
and 88 pi of thrombin. Approximately 100 pi of the mixture was injected into fibrin- 
coated tubes and allowed to incubate for 1 h at 37°C.
Following clot formation, the capillary tubes were connected to Tygon tubing and 
a 5 ml glass pipette filled with a solution of 5 ml PBS, 2 ml PPP, and the study 
formulation consisting of 10% labeled streptokinase and 90% unlabeled plasminogen 
activator.
Microscopy studies
Real-time video of plasma clot lysis with light microscopy was acquired using a 
5x Plan-Neofluor objective on a Zeiss Axiovert 200 equipped with a Dage-MTI cooled 
CCD-300. Images were processed prior to being recorded using an Argus-20 Image 
Processor (Hamamatsu) and recorded on a Sony SVO-9500MD Videocassette Recorder 
using S-VHS video tapes for greater resolution. The images were captured digitally 
using a Flashbus MV Video Frame Grabber and analyzed with Metamorph Version 4.6r8 
software (Universal Imaging Corporation).
Plasma clot lysis with confocal microscopy was observed with an Olympus XL 
Fluor 4X objective equipped with a 0.28 numerical aperture on an Olympus Fluoview 
FV-500 Confocal Laser Scanning Biological Microscope. The optical resolution (about 
3.2 pm in the x- and y-directions) allowed for an adequate view of both the thrombus 
front and at least 2 pm of the thrombus interior. Samples were fluoresced using Argon
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488 and Helium-Neon 543 lasers. Images were collected in 20 ^un slices; collecting a 
single complete image took 40 s. Images were analyzed with Olympus MicroSuite B35V 
software (Soft Imaging System) to determine the intensity of the fluorescence signal as a 
function of position in the clot.
STATISTICS
Using the Student's t-Test, p values < 0.05 were considered significant. Unless 
otherwise stated, all data are presented as the mean ± standard error of the mean.
RESULTS
Streptokinase microencapsulation efiiciency
The efficiency of the encapsulation process was measured in three ways: 1) total 
mass of product at the completion of preparation; 2) concentration of entrapped protein 
using a protein assay; and 3) the activity of the entrapped enzyme. At the conclusion of 
preparation, 91.2 ± 0.8% [n=l 1] of the total product was recovered.
The concentration of the encapsulated protein was determined with a commercial 
protein assay kit (Pierce, Rockford, IL) based on the Lowry method of protein 
determination. Microparticles (10 mg in 1 ml PBS) were allowed to dissolve completely 
at room temperature. The streptokinase concentration in each sample was compared to a 
standard curve of protein in an identical concentration of polymer. A m^ority of the 
initial protein, 90.0 ± 3.9%, was entrapped within the microparticles as observed with this 
assay.
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Viable streptokinase content in the microparticles was quantified using a 
commercial chromogenic activity assay (Helena Laboratories, Beaumont, TX). The 
microparticles were allowed to dissolve completely in distilled water for at least 2  h, a 
period sufficient for complete dissolution. This process was followed and confirmed by 
light scattering studies using a Coulter LS Particle Size Analyzer (Beckman-Coulter, 
Fullerton, CA). The activity of each sample, characterized as the ability of streptokinase 
to cleave plasminogen and form plasmin, was compared to that of a standard curve of 
streptokinase in the presence of an identical blank microparticle concentration. Although 
most of the protein was encapsulated as evidenced by the protein concentration assay, a 
significant portion of the enzyme was deactivated during the process, with observed 
sample activity of 55.5% ± 5.3% of an identical concentration of non-encapsulated 
streptokinase.
Measurement of clot lysis
Fibrinolysis of whole blood and plasma clots was investigated by administering a 
perfusate of various streptokinase formulations (n= 8  for all groups) with the results 
presented in Tables 4.1 and 4.2. Three general trends can be observed: 1) Clot lysis is 
accelerated by increases in pressure drop for either clot type and with all thrombolytic 
formulations; 2) clot lysis is accelerated with MESK versus either free streptokinase 
formulation; and 3) clot lysis is retarded by the infusion of FREE SK + BLANK. 
Additionally, infusion of the higher concentration per particle formulation of MESK (HI 
MESK) often resulted in further reduction in lysis times compared to MESK,
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10 mmHg/cm 
(min)
20 mmHe/cm 
(min)
30 mmHe/cm 
(min)
Averaee Chanee 
from FREE SK 
(%)
FREE SK 46.0 ± 5.3 26.4 ± 1.5 19.1 ± 1.8 —
FREESK  +
BLANK 55.9 ±3.6 34.1 ±3.6 27.9 ± 1.8* + 32.3 ±7.3
MESK 46.5 ±4.7 19.4 ± 1.5* 14.1 ± 1.4* - 17.2 ±9.2
[HI] MESK 31.8±2.7*t 18.5 ±0.9* 14.4 ±0.7* -28.5 ±2.0
Table 4.1: Whole blood clot lysis times at various initial pressure drops with four
formulations of streptokinase (mean ± SEM).
* = p <  0.05 vs. FREE SK; f  = p < 0.05 vs. MESK
5 mmHe/cm 
(min)
10 mmHe/cm 
(min)
15 mmHe/cm 
(min)
Averaee Cbanee 
from FREE SK
FREESK 30.1 ±3.4 29.1 ± 1.9 17.8 ± 1 .6 —
FREE SK +
BLANK 40.0 ±8.1
36.4 ±3.3* 20.4 ±3.2 + 24.2 ±5.3
MESK 23.9 ±3.3 23.8 ± 1.0* 12.0 ± 1.4* -23.8 ±4.5
[HI] MESK 21.1 ± 1.3* 13.1±0.8*t 1 0 .8  ± 0 .6 * -41.4 ±7.3
Table 4.2: Plasma clot lysis times at various initial pressure drops with four 
formulations of streptokinase (mean ± SEM).
* = p < 0.05 vs. FREE SK; f  = p < 0.05 vs. MESK
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although usually not a statistically significant reduction.
Interestingly, lysis of whole blood clots with FREE SK was preceded by a 
significant portion of erythrocytes passing through the clot, leaving a clot composed 
primarily of plasma and fibrin. Although some level of lysis had already occurred, clot 
dissolution proceeded more rapidly due to the reduction in resistance from erythrocytes. 
The phenomenon of erythrocyte washout has been reported previously [79]. However, 
erythrocyte washout was not observed with MESK- or FREE SK + BLANK-treatment of 
clots.
By visualization of clot lysis through an Olympus BH-2 light microscope 
equipped with a 4X objective, the method of fibrinolysis for FREE SK and MESK 
appeared quite different. FREE SK appeared to dissolve the clot from the leading edge 
alone, and movement of the front could be observed with the naked eye. Channeling, 
also known as dissolution fingering, regularly occurred through the clot, which was a 
function of the pressure drop over the length of the thrombus. The channeling 
phenomenon has been previously reported as a function of the applied convective forces 
[33, 34, 36]. Oftentimes there was a substantial portion of the thrombus remaining on the 
tube wall when flow was restored. Clots treated with FREE SK + BLANK exhibited 
similar behavior.
In contrast to FREE SK, thrombus exposure to MESK resulted in the formation of 
voids due to lysis in advance of the clot's leading edge (Figure 4.2). A sufRcient 
concentration of streptokinase was allowed to penetrate the front and begin dissolution 
within the thrombus. In collecting real-time video of plasma clot lysis, two frames were 
isolated that demonstrate dissolution with FREE SK (Figure 4.3). The leading edge
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oFigure 4.2: Microscopic view of whole blood (A) and plasma clot (B) undergoing distributed intraclot 
thrombolysis upon infusion of MESK.
LA
FREE SK at 675 sec
FREESK at 679 sec
MESK at 671 sec
MESK at 675 sec
Figure 43 : Frames of real-time video of plasma clot lysis using light microscopy. The leading edge of the 
thrombus is highlighted in blue.
of the clot moves slowly and in a predictable fashion. Frames isolated from an MESK- 
treated clot at approximately the same time period illustrate a very different method of 
lysis. The &ont moves faster with more of the thrombus dissolving in both the x- and y- 
planes instead ofjust one-dimension as seen with FREE SK.
Similar techniques were utilized to examine clot lysis with confocal laser 
scanning microscopy. As observed with light microscopy, FREE SK tended to bind to 
the thrombus front, as demonstrated by the intense region of fluorescence at the 6 ont 
(Figure 4.4A). When considering the map of fluorescence versus position extracted from 
the streptokinase concentration (Figure 4.5, bottom left), one significant peak of 
fluorescence intensity routinely occurred at the 6 ont, verifying the high concentration of 
streptokinase. MESK-treated clots resulted in improved permeation of streptokinase as 
evidenced by the formation of voids in the interior of the clot (Figure 4.4B). These voids 
were similar to those seen with light microscopy. Fluorescence mapping of a thrombus 
treated with MESK demonstrated multiple peaks of fluorescence as a function of position 
(Figure 4.5, bottom right), suggesting greater distribution of labeled streptokinase, an 
occurrence not seen with FREE SK. As seen in Figures 4.4 and 4.5, streptokinase is 
dispersed more effectively within the thrombus with MESK, while most of the FREE SK 
is bound to the leading edge. This is potentially due to decreased streptokinase 
adsorption to the front with MESK compared to FREE SK, thereby allowing greater 
penetration of the thrombus.
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FREE SKAT 2 MIN ^  FREESK AT 4  MIN
MESK AT 2 MIN B  MESK AT 4 MIN
Figure 4.4: Confocal microscopy is used to monitor clot lysis with FREE SK (A) and MESK. (B).
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Figure 4,5: Greater distribution of streptokinase is observed witii MESK (top right) compared to FREE SK (top left) by 
increased fluorescence of streptokinase within the clot (bottom).
DISCUSSION
Administration of liposomal encapsulated plasminogen activators has 
demonstrated enhanced clot lysis in numerous m vitro and in vivo models [22-26]. 
Multiple endpoints are dramatically improved such as a reduction in the time to obtain 
reperfusion and a greater percentage of dissolved thrombus. Encapsulation of 
streptokinase in polymer microparticles has shown comparable benefit to liposomal 
encapsulated streptokinase with improved shelf-life (Chapter 3). In these studies, 
accelerated reperfusion times have been demonstrated using microencapsulated 
streptokinase in viiro.
Multiple reports have demonstrated the occurrence of clot lysis from the leading 
edge alone with freely administered plasminogen activators [32, 34, 81-83]. Plasminogen 
activators normally bind to the clot front due to protein adsorption at the surface. The 
results of frontal-edge binding can be seen by the routine occurrence of steady frontal 
lysis or channeling, in which clots are dissolved from the front at the site of the lowest 
pressure drop across the length of the clot. Although the formation of a channel allows 
the restoration of much-needed blood flow, a large portion of the clot often remains on 
the vessel wall in the form of a mural thrombus. The presence of residual clot on the 
walls results in reduced available cross-sectional area for flow and increased probability 
for reocclusion.
In order to examine the ability of encapsulated streptokinase to digest thrombi of 
varying composition and in different conditions, a simple in vitro system has been 
utilized. As seen in Tables 4.1 and 4.2, reperfusion times were reduced with increasing
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initial pressure drops for both whole blood and plasma clots when using MESK 
compared to identical dosages of FREE SK.
This simple in vitro model has the benefit of few variables to control, thereby 
allowing the investigator to look closely at the effect of one component (i.e. encapsulated 
vs. free streptokinase). However, the simplicity of the system results in several 
significant shortcomings. Many proteins, including plasminogen activators, perform 
quite differently at various temperatures. Performing the experiments at room 
temperature (25°C) compared to an ideal physiological temperature (37°C) undoubtedly 
results in slower clot lysis. Despite likely increases in clot lysis when performing tests at 
37°C, the comparisons between study groups are still valid as all were examined at the 
same temperature. Also, this system does not afford the opportunity for removal of free 
or encapsulated streptokinase. This missing factor deviates from the in vivo setting in a 
manner that likely skews the differences that might be observed with MESK over FREE 
SK. Lastly, the applied pressure must be kept constant by the investigator, opening the 
door for experimental error to become prevalent.
The mechanism for encapsulated lytic agents' improvement has only been 
proposed in earlier studies. The most plausible theory is that encapsulation or entrapment 
protects the enzyme from premature inactivation or removal while in the circulation. 
Protection of the agent effectively lengthens the half-life and circulation time of the 
agent, thereby allowing a greater concentration of thrombolytic agent to convert 
plasminogen into plasmin. While the continued protection of these agents is likely to 
play a role in its efficacy, results from these experiments have elucidated a more precise 
mechanism for the success of encapsulated plasminogen activators.
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In this chapter, evidence is presented in support of a hypothesis entitled 
Distributed Intraclot Thrombolysis (DIT) as a mechanism for thrombolysis with MESK. 
In contrast to free streptokinase which works through a series of localized reactions at the 
leading edge, MESK avoids significant adsorption at the &ontal edge of the clot and is 
allowed to penetrate to the interior portion of the thrombus. Images collected with 
confocal microscopy verify greater concentrations of streptokinase within the thrombus 
with MESK compared to FREE SK at identical times (Figure 4.4B). As streptokinase is 
dispersed throughout the polymer vehicle, the protein is continuously released as the 
particle erodes, resulting in both free streptokinase and encapsulated streptokinase 
arriving at the site of occlusion. The streptokinase released by MESK on the interior of 
the thrombus results in the formation of voids within the clot.
Permeation of the thrombus by MESK might also provide a method to limit 
"plasminogen steal," the effect of plasminogen depletion that occurs in the presence of 
non-fibrin-specific plasminogen activators. This phenomenon relates to the movement of 
clot-bound plasminogen out of the clot and into the plasma compartment as a result of 
depletion of plasminogen in the outer plasma by plasminogen activators and the 
occurrence of a concentration gradient. Encapsulation limits the total concentration of 
&ee plasminogen activator at the surface of the clot, and although not specifically 
considered in this study, should limit the depletion of plasminogen in the circulation.
Decreased adsorption is likely a function of two factors: 1) the material and 2) 
sequestration of the drug within a vehicle. Polyethylene glycol is known to resist plasma 
protein adsorption, an appealing characteristic for this application. Secondly, only 
streptokinase that is released into the fluid phase is hee to bind to the clot. Streptokinase
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entrapped within the particles cannot react with plasma proteins and is permitted to 
continue progressing through the clot until its release from the vehicle.
In order to better understand some of the factors associated with clot lysis using 
FREE SK and MESK, a numerical simulation has been developed and described in 
Chapter 5.
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NUMERICAL ANALYSIS OF CLOT LYSIS WITH FREE and 
MICROENCAPSULATED STREPTOKINASE
CHAPTERS
INTRODUCTION
The limitations of molecular transport of plasminogen activators during 
thrombolytic therapy have not been well appreciated. Understanding and addressing 
these limitations could dramatically enhance the performance and improve the promise of 
these agents for treatment of cardiovascular crises. The same affinity of the plasminogen 
activators for fibrin necessary to achieve the clot digestion ultimately tmdermines the 
species' effectiveness in restoration of blood flow. More specifically, this strong affinity 
coupled with the high surface area of the fibrous fibrin network and the extremely slow 
flow into the clot results in rapid removal of the plasminogen activator shortly after blood 
enters a thrombus. Plasminogen activation therefore occurs primarily at the leading edge 
of the clot. The localization of the reaction near the liquid-solid interface has been 
demonstrated using in vitro experiments and computational modeling of lysis of fibrin 
gels in capillary tubes [32, 34, 80-82].
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Results from in vivo (Chapters 3 and 6 ) and in vitro (Chapter 4) studies confirm 
that enhanced thrombolysis is achieved with microencapsulated streptokinase compared 
to free streptokinase. As described in Chapter 4, evidence is growing to support the 
hypothesis that enhanced thrombolysis with encapsulated plasminogen activators occurs 
as a result of distributed intraclot thrombolysis. In short, this theory puts forth that the 
encapsulation vehicle facilitates penetration of the plasminogen activator into the clot by 
inhibiting adsorption. As a result, fibrinolysis occurs throughout the clot in 3 dimensions 
(x, y, and z) instead of being restricted to 2  dimensions (x and y) as observed with free 
agents. Figures 4.2-4.5 show that encapsulated streptokinase digests thrombi in a very 
difkrent manner than hee streptokinase, with greatly improved spatial lysis occurring 
with encapsulated streptokinase. In order to better understand the mechanism of clot 
lysis with microencapsulated streptokinase, a first-generation computational analysis has 
been developed.
METHODS
Clot lysis by streptokinase is described using a convection-diffusion-reaction 
equation which takes into account the adsorption of free species to the thrombus. The 
thrombus has been modeled as a homogeneous, isotropic structure with a horizontal 
orientation. The problem has been reduced to changes in only one-dimension (the x- 
direction). To facilitate the modeling of thrombus digestion, the appropriate equation is 
the species mass transport equation:
6 0
= 0 (5,1)
where Næüvator is the molar flux through a region, 6 Cactivator/  ^is the rate of accumulation, 
Ractivator is the loss of plasminogen activator through reactions, and Aactivaior is the loss of 
plasminogen activator through reversible adsorption.
Enzymes &om blood may be introduced by diffusion and convection into the 
thrombus through a single plane, which is referred to as the blood-thrombus boundary.
As the thrombus dissolves, the blood-thrombus boundary moves into the positive 
direction of the clot (x-direction). To simplify the problem, velocity of interstitial fluid is 
calculated from in vitro studies described in Chapter 4 and held constant, an assumption 
previously implemented by Blinc in earlier models of thrombolysis [13]. Therefore, 
changes in pressure drop over the length of the clot are not considered. Additionally, 
physical characteristics of the clot such as permeability and porosity are held constant; 
properties that would otherwise be changing during clot digestion. The thrombus initially 
contains no functional streptokinase, and the concentrations of bound plasminogen and 
antiplasmin within the thrombus are taken as constant.
The conversion of plasminogen to plasmin by streptokinase is modeled by a series 
of reversible and irreversible reactions which occur in the fluid phase of a thrombus:
1 . + (k]/k.|) (5.2)
2 . -  f I G  4- fTG  -4 -  fZG  + fZM (kz) (5.3)
3. W (5.4)
4. f  AM + f f  AM + FD f (k4) (5.5)
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where SK. is free streptokinase, PLG is plasminogen, SK-PLG is the streptokinase- 
plasminogen complex, PLM is plasmin, PLM-AP is plasmin inactivated by a^- 
antiplasmin, FBN is fibrin, and FDP is fibrin degradation products. The reaction rate 
constants, kj, are identified in parentheses after each reaction.
The adsorption of various species to the thrombus from the fluid phase drives the 
dissolution of the clot. Adsorption is modeled using a Langmuirian-type isotherm in 
which the amount of adsorbed species to vacant sites on the thrombus is directly 
proportional to the concentration of the species. For example, the change in 
concentration with respect to time of plasmin is described by the following equation:
— CpLM  ^ = kADS^^^ CpLM  ^ (epLM'^-CpLM^) -  koES^^^ CpLM^
at (5.6)
where the superscript "b" represents bound species, " f ' represents fluid species, 6  is the 
concentration of available vacant sites, and k*DS and koES are the kinetic constants of 
adsorption to and desorption from the thrombus, respectively.
When all components are integrated into the equation, the general form of the 
convection-diffusion-reaction equation utilized in this model is represented as follows:
- C /  =
at ax
. I c i "
at
+ ZR
(5.7)
where D is the diffusion coefficient of species "i" through the fluid phase, v is the 
velocity of the interstitial fluid, G is the porosity of the thrombus, and ZR is the 
summation of ongoing homogeneous and heterogeneous reactions. Similar equations are 
written for each species with accompanying boundary conditions listed in Appendix B.
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Release of streptokinase &om the microparticles is modeled using the Hixon- 
Crowell equation [83]. This model is based on the requirement of the particle surface 
area being proportional to the cubic root of its volume. Therefore, the following equation 
was generated:
1 1
^ 0  " ^ t  (5 .8 )
where Wo is the amount of drug within the particles initially, Wt is the amount of drug in 
the particles at time t, and K is the release rate. Dividing the left side of equation 5.8 by 
Wo^  ^and simplifying gives:
2
(5.9)
where f] is the fraction of drug released at time t. A plot of the left-hand side of the 
equation versus t will generate the release rate constant, K, as the slope.
When the Hixon-Crowell model is used, it is assumed that the release rate is 
limited by the drug particles' dissolution rate and not by the difftision that might occur 
through the polymeric matrix [83]. The model also assumes that the particles diminish 
proportionally over time.
The addition of MESK to the system requires a fifth reaction with an appropriate 
reaction rate.
5. (ks) (5.10)
where k; is the dissolution rate/release rate from the polymer as determined using the 
Hixon-Crowell model.
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In order to calculate changes in species concentration with respect to both position 
and time, a finite-difference technique using a central difference method to approximate a 
derivative and the Crank-Nicolson method to approximate second derivatives has been 
implemented to arrange equation 5.7 into a mathematically tractable set of equations [84- 
8 8 ]. A full description of the model's derivation including all assumptions is available in 
Appendix B. The FORTRAN codes are located in Appendix C.
Clot lysis was determined by changes in fibrin concentration. The clot was 
considered digested at a specific position when the fibrin concentration dropped to 2/3 of 
its baseline level. When the hbrin concentration dropped below 3.882 pM, a zero was 
installed in the matrix. Minimum levels of various concentrations were defined within 
the simulation to facilitate stability of the calculations. Streptokinase dosage was 2500 
lU in 7 ml of fluid (0.76 pM) to be consistent with in vitro studies discussed in Chapter 4.
The model was executed using a Pentium III 900 MHz processor with a 
FORTRAN compiler. In order to maintain stability of the model during calculations, 
time steps of 0.01 seconds (1.67E-3 min) and position steps of 0.015 cm were used. Clot 
lysis was modeled for a maximum of 30 minutes. Simulations of 30 minutes of clot lysis 
required approximately 15 minutes of computation time. Other parameters are listed in 
Table 5.1. A flowchart describing the calculation process is shown in Figure 5.1.
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MODEL PARAMETER VALUE REFERENCE 
Diamond and Anand
Diffusivity of proteins (D) 3.00E-06 cm /min (1993)
Diffusivity of MESK (DwESK) 5.00E-08 cm^/min —
kADs for SK-PLG to fibrin 5.75E-03 pmol/(L*min) Fears et al. (1985)
koES for SK-PLG to fibrin 3.99E-03 m in ' Fears et al. (1985)
8  (available sites) for 
SK-PLG to fibrin
0.39 pmol Anand et al. (1997) 
Diamond and Anand
kADS for plasmin to fibrin 3.00E-02 pmol/(L*min) (1993)
Diamond and Anand
koES for plasmin to fibrin 3.26E-03 min'' (1993)
Diamond and Anand
0  (available sites) for 
plasmin to fibrin
1 .0 pmol (1993)
kADS for MESK to fibrin 5.75E-05 |imol/(L*min)
koES for MESK to fibrin 3.99E-05 m in '
0  (available sites) for 
MESK to fibrin
0.39 pmol
Tuliani and O'Rear
ki 60 min"' (1988)
Tuliani and O'Rear
kwi 1.80E-03 m in' (1988)
Tuliani and O'Rear
kz 2 2 . 0 2 m in' (1988)
Tuliani and O'Rear
k] 0.24 min"' (1988)
Tuliani and O'Rear
k4 1500 min"' (1988)
Table 5.1: Model parameters for simulations.
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Figure 5.1: Flowchart for simulations of clot lysis with FREE SK and MESK.
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RESULTS 
f re e  g
The ability of the model to accurately describe clot dissolution was examined first 
for free streptokinase. As predicted by Darcy's law, one would expect clot lysis to be 
more rapid at higher fluid velocities. Therefore, the constant velocity was varied from its 
initial value of 0.095 cm/min to both 0.95 cm/min and 0.0095 cm/min, and clot lysis was 
simulated with all other parameters remaining constant.
As seen in the top panel of Figure 5.2, fluid velocity has a significant effect on 
clot lysis times. More than 70% of the clot was digested in 30 minutes at 0.095 cm/min. 
When the velocity is increased by an order of magnitude, more than 70% of the thrombus 
was digested in less than 3 minutes. In this case full clot lysis is not evident, most likely 
because a m^ority of the free streptokinase moves through the clot too quickly. When 
velocity is reduced to 0.0095 cm/min, less than 10% of the clot is degraded in the 30 
minute simulation. This velocity approximates the condition of diffusion-mediated 
transport alone, a condition described previously [28, 33].
It is also logical to expect that clot lysis would proceed faster with a greater initial 
concentration of plasminogen activator. To examine the effect of streptokinase 
concentration, initial streptokinase levels were examined at 0.076, 0.76, and 7.6 pmol 
(Figure 5.2, bottom). Streptokinase concentrations of 0.76 pM correspond to 
concentrations used in humans (-300 lU/ml or 1.5e6 lU). More than 70% of the clot was 
lysed in 30 min using the baseline value of 0.76 pmol, while only 50% dissolved at 0.076 
pmol. The entire clot was digested at the highest initial concentration of streptokinase.
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Figure 5.2: Clot lysis with FREE SK is greatly aHected by fluid velocity (top) and 
initial concentration of free streptokinase (bottom).
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This high concentration, however, is not a viable clinical option due to the greatly 
increased potential for severe bleeding.
Based on reasonable changes in clot lysis when implementing order-of-magnitude 
variations of multiple parameters, the model for &ee streptokinase appears adequate 
based on these assumptions. Clot lysis results from in vitro studies using h-ee 
streptokinase in Chapter 4 were utilized to gauge the model's accuracy at one initial 
pressure drop. Comparing the simulation to FREE SK lysis of plasma clots at an initial 
pressure drop of 10 mmHg/cm-clot (0.095 cm/min), the model seems to perform properly 
(Figure 5.3). However, the model deviates from experimental values when the pressure 
drop (i.e. velocity) is increased to 15 mmHg/cm-clot (0.118 cm/min).
Based on reasonable results with the FREE SK simulation, the MESK model was 
examined for changes in clot lysis upon variation of parameters such as diffusion 
coefficient, adsorption/desorption to fibrin, and particle dissolution rate. As in the 6 ee 
streptokinase model, velocity was calculated from in vitro experiments in Chapter 4 and 
held constant. Thrombus porosity was also held constant. Lastly, drug release rate was 
calculated from the Hixon-Crowell model based on in vitro release of bovine serum 
albumin from microparticles and estimated at 0 . 0 2 2  min"'.
For this first-generation simulation, the diffusion coefficient of the microparticles 
was held constant despite the decreasing size of the particles as they erode. An average 
diffusion coefficient was calculated as described in Appendix B and installed in the
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Comparison of Predicted and Experimental Lysis with FREE SK
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Figure 5.3: Comparison of model results to experimental lysis of plasma clots with FREE SK at 10 and 
15 mmHg/cm-clot.
simulation with a value of 5.0E-8 cm^/min. Using the Stokes-Einstein relationship, 
diffusion coefficient corresponds inversely to particle size. As particle diameter 
increases, the diffusion coefBcient will get smaller. This enables the simulation to 
examine variations in particle size. Sensitivity of clot lysis to changes in diffusion 
coefficient was examined with values of 5.0E-6, 5.0E-8, and 5.0E-10 cm^/sec.
Simulation results in Figure 5.4 (top) demonstrate that clot lysis is not sensitive to 
changes in diffusion coefBcient for this model. However, the time to achieve clot lysis is 
accelerated to just under 8  min with MESK at any diffusion coefficient with the 
prescribed kdiMoive=0 . 0 2 2  m in'\
The effect of streptokinase release was examined by varying the release rate 
(kdissoive) of drug 6 0 m the microparticles at 0.0022, 0.022, and 0.22 m in '. It is expected 
that faster release of streptokinase 6 0 m the microparticles would translate into faster clot 
digestion. Results from variations in drug release rate are shown in Figure 5.4 (bottom). 
As expected, increases in release rate from result in significantly faster clot digestion. 
Based on the faster dissolution than that observed in vitro, it is suspected that the initial 
calculation of kjiMoivcis too large.
To quantify the effect of adsorption of the microparticles to the thrombus, order- 
of-magnitude variations in these values were simulated. As there are no previously 
determined values, it was assumed that the rates are dramatically slower than free 
streptokinase, as polyethylene glycol is known to resist adsorption. For this reason, this 
phenomenon was investigated at kads values on the order of E-1, E-3, and E-5 
pmol/(L*min). The rate of adsorption was varied with higher and lower release rates 
than 0 . 0 2 2  min"', and no significant changes were observed in clot lysis with this model.
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Figure 5^: Clot lysis with MESK is not aKected by changes in microparticle diffusion 
coeHicient (top), but is signiGcantly affected by drug release rate (bottom).
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The lack of sensitivity to rates of adsorption and desorption was unexpected. In 
short, the MESK model is currently only sensitive to changes in velocity, streptokinase 
concentration, and release rate. However, increased distribution of streptokinase 
throughout the clot has been observed experimentally using confbcal microscopy with 
MESK (Figure 4.5) compared to &ee streptokinase, where most of the agent is adsorbed 
to the leading edge. Simulations examining the movement of &ee streptokinase show 
increasing distribution of the agent over time throughout the clot (Figure 5.5, top), a 
result in stark contrast to FREE SK simulations. Depressions in fibrin concentration 
within the thrombus approximate the void formations observed in vitro in Chapter 4 
(Figure 5.5, bottom). Due to increased spatial distribution of drug, it is likely that the 
limitations and assumptions of this model are prohibiting substantial differences from 
becoming obvious.
Clot lysis results 6 om in vitro studies using MESK in Chapter 4 were utilized to 
gauge the model's accuracy at one initial pressure drop. Comparing the simulation to 
MESK lysis of plasma clots at an initial pressure drop of 10 mmHg/cm-clot (0.08 
cm/min), the model seems to perform adequately at later times provided the release rate 
constant is changed to 0.0033 min'^ (Figure 5.6). Due to the definition of clot dissolution 
(fibrin reduction of 2/3), the model does not compare well at early times.
DISCUSSION
A first-generation model of clot lysis with &ee and microencapsulated 
streptokinase has been developed based on the convection-diffusion-reaction mass 
transport equation. The model of 6 ee streptokinase is sensitive to initial streptokinase
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Figure 5.5: Despite the lack of sensitivity to changes in kAos. Abrin concentration is
reduced in the interior of the clot compared to the leading edge (top), while 
streptokinase concentration increases over time (bottom).
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Comparison of Predicted and Experimental Clot Lysis with MESK
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fig u re  5.6: Comparison of MESK lysis of plasma clots at 10 mmHg/cm-clot to simulation with release rate of 
KdiMo)ve= 0.0033 m in'\
concentration, porosity, and velocity. The simulation approximates experimental data of 
plasma clot lysis at 10 mmHg/cm-clot (Figure 5.3).
The model of lysis with MESK is presently sensitive only to velocity, initial 
streptokinase concentration, and release rate. Based on observations using confbcal 
microscopy, it was expected that the model would be sensitive to changes in rates of 
adsorption to fibrin. However, no significant changes were observed when the adsorption 
rate of MESK was varied over four orders of magnitude.
The lack of sensitivity to changes in adsorption is likely due to the assumptions 
and idealization of the model. First, Darcy's law was not utilized. A constant velocity 
was calculated instead from in vitro studies and installed in the simulation. As clots 
shorten during lysis, the velocity of interstitial flow accelerates, thereby carrying more 
plasminogen activator into the thrombus and speeding digestion. Secondly, the release of 
streptokinase from the microparticles is assumed to be a first order reaction in which 
streptokinase is either entrapped within the polymer or is in the free circulation. It is 
possible that the microparticles release the drug in a different fashion with an 
intermediate. The intermediate complex would consist of streptokinase with attached 
polyethylene glycol. The corrugated PEG would limit adsorption to the thrombus as seen 
with confbcal microscopy (Figure 4.5, left). Perhaps the addition of more reactions might 
capture the effect of adsorption. As mentioned above, the solution is not iterated. 
Therefbre, more precise values would likely be achieved fbllowing an iterative solution 
technique. Lastly, the presence of clot is represented in this model as an "on/off" option, 
in which fibrin concentration must be above 3.882 pM (2/3 of the baseline value) or else
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there is no clot. In reeility, fibrin remains at lower concentrations and persists due to other 
variables that have not been considered in this model.
The computer simulation as currently written suffers &om a deficiency in its 
solution method. Initially, the problem was attempted using an explicit method of 
solution which solves for the concentrations at the next time step using only known 
concentrations 6om previous time steps. This is an effective way to solve such a 
problem, but it requires very small times steps in order to maintain stability. In short, 
there is a large charge in computation time when using the explicit method. The 
hardware and software utilized to solve this simulation with the explicit method was not 
sufficient to maintain stability and collect output.
The implicit method, as utilized in this model, requires information &om future 
time steps to solve for concentrations at future time points. Concentrations for the entire 
system are calculated and the system is solved iteratively until differences between 
concentrations are within a prescribed and acceptable error. Implicit techniques are 
inherently more stable than explicit techniques with a similar charge in computation time.
In this model, an iterative solution technique has not been implemented due to the 
available resources and time to achieve measurable changes in species concentrations. 
Output files, when dumped into a spreadsheet for manipulation, routinely exceed 70 
megabyte in size. This results in a significant strain on computer resources. Secondly, 
iterative calculations are often continued when the change in concentrations is within a 
certain acceptable error. For this system, the change in species concentrations is minute 
for long periods of time, making the traditional guidelines for iterative calculations 
unfeasible.
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In conclusion, this first-generation model requires much greater hardware and 
software resources to utilize an explicit method or an interative solution technique with 
improved hardware resources using an implicit method. Addition of either suggestion 
should provide improved results with this first-generation model.
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ASSESSMENT OF THROMBOLYTIC EFFICACY OF 
MICROENCAPSULATED STREPTOKINASE IN A 
CANINE MODEL OF CORONARY ARTERY THROMBOSIS
CHAPTER 6
INTRODUCTION
In order to determine the potential benefit of clot-busting formulations in a 
clinically relevant situation, canine models of coronary artery thrombosis have been 
utilized to investigate the efficacy of thrombolytic formulations for treatment of acute 
myocardial infarction [22, 23]. Canines are a particularly good model to examine 
fibrinolytic agents for two reasons. First, the vessels of the canine are much larger than 
other animals which might be used for such investigations, namely rabbits, rats, and 
mice. This makes the surgical procedures more technically feasible for investigators. 
Perhaps more importantly, canines develop collateral vessels in the early course of their 
life, much like older humans. The collateralization phenomenon allows one to study 
fibrinolytic agents in a healthy specimen instead of the older or diseased specimens in
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other species which would be required to simulate humans. While the results obtained 
with encapsulated streptokinase in the rabbit model of carotid artery thrombosis are 
promising (Chapter 3), there is a need to examine this formulation in a more clinically 
relevant model.
Due to the large size of the animal, small modifications in the preparation of 
MESK were required in order to encapsulate enough streptokinase in a tolerable mass of 
polymer. To achieve this level of encapsulation, a larger initial concentration of 
lyophilized concentration was added to the polymer solution (250,000 lU/ 2 gm PEG) 
compared to that used in the rabbit studies (80,000 IU/1 gm PEG). Additionally, the 
effect of streptokinase concentration per particle was investigated in two small groups by 
preparing both high and low concentration per particle dosage forms relative to the 
formulation used in the majority of canine MESK studies. The variations in 
concentration per particle were achieved by varying the initial mass of PEG while 
keeping the initial streptokinase concentration constant.
MATERIALS AND METHODS
Streptokinase (SK) was entrapped in a water-soluble polymer through a modified 
double emulsion method [70, 71]. Briefly, polyethylene glycol (PEG, 2 gm, 20,000 MW; 
Polysciences, Inc.) was dissolved at room temperature in 3 mL chloroform (Fisher 
Scientific, Pittsburgh, PA) and SK (Streptase®, 250,000 lU, Behringwerke AG) was 
dissolved separately in 0.4 mL distilled water. Aqueous protein solution was added to the 
polymer solution and immediately dispersed by sonication at 40-50 W for 1 min. The
8 0
protein/polymer solution was mixed with 8 mL of 2% (w/v) polyvinyl alcohol (PVA, 
average MW 30,000-70,000, Sigma Chemical) and vortexed 20 s. The mixture was 
placed in a freezer at -80°C for 2 h and then lyophilized for 15-20 h. The lyophilized 
product was washed with hexane in a centrifuge at 600 x g for 10 min at 4°C, and then 
filtered under vacuum through 0.45 pm membranes to remove any externally bound 
protein, and dried in a fume hood for 1 h. The preparation process was repeated to insure 
the availability of an adequate dosage for the experiment. Final product composed of 
porous, mostly spherical particles with an average diameter of 0.810 ± 0.054 pm (n=13; 
mean ± SD) was then stored at room temperature until use. Particle size was determined 
by light scattering studies using a Coulter LS Particle Size Analyzer. A blank 
formulation was prepared by replacing the SK solution with an identical volume of 
distilled water and completed as described above. High concentration per particle 
formulations (HI MESK; n=3) were prepared by adding 250,000 lU streptokinase to 4 
gm PEG, while LO MESK (n=3) was prepared by adding the same concentration of 
streptokinase to 8 gm PEG.
SK content in the microparticles was quantified by verifying protein concentration 
and protein activity. The concentration of encapsulated protein was determined with a 
commercial protein assay using bicinchoninic acid (Pierce Chemical) after dissolving the 
microparticles (10 mg in 1 mL PBS) completely. SK concentration in each sample was 
determined spectrophotometrically using a standard curve of SK with blank 
microparticles at identical concentrations.
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Activity of entrapped SK was determined using a commercial chromogenic assay 
(Helena Laboratories). Microparticles (5 mg in 1 mL PBS) were allowed to dissolve 
completely in distilled water for at least 45 min. Samples were collected, incubated with 
plasma, and the kinetics of plasminogen-SK complex formation were determined 
spectrophotometrically at 405 nm as a measure of SK activity by fbllowing the release of 
/?-nitroaniline from the chromogenic substrate. Samples were compared to that of a 
standard curve of SK with blank microparticles.
mode/
The fibrinolytic activities of various formulations of free and encapsulated 
streptokinase were examined in a canine model of coronary thrombosis (Figure 6.1) 
originally described by Kopia and co-workers [90] and modified in our laboratory [22]. 
Animals were treated under procedures that were examined and approved by the 
Institutional Animal Care and Use Committee of the University of Oklahoma Health 
Sciences Center and the University of Oklahoma, Norman. Male dogs (15-25 kg) were 
anesthetized and maintained with intravenous sodium pentobarbital (30 mg/kg). An 
endotracheal tube was inserted to respire the animal with room air using a Harvard 
ventilator. Cannulae were inserted into the left and right femoral veins for drug 
administration. An electrocardiogram (V-2) was measured from the body surface for the 
duration of the experiment.
A leA thoracotomy was performed in the fourth intercostal space and the heart 
exposed. The leA anterior descending coronary artery was isolated at the tip of the leA 
atrial appendage. Coronary artery Aow was measured with a 20-MHz pulsed Doppler
82
00w
Figure 6.1: Canine model of coronary artery thrombosis. On the left is a cartoon diagramming the placement of the occlusive 
thrombus within the left anterior descending coronary artery, as well as the placement of the Doppler flow cuff to 
monitor velocity of flow. On the right is an image of a canine heart used in this in vivo study. Cartoon is courtesy 
of Dr. Eugene Patterson.
probe. Autologous whole blood (0.1 mL) was withdrawn slowly over 10 s &om the 
coronary artery into a glass syringe containing approximately 100 units thrombin (Sigma 
Chemical). The autologous blood with thrombin was injected into an ensnared 5-10 mm 
long segment of the leA anterior descending coronary artery. AAer 10 min, the proximal 
ligature was released, as was the distal ligature aAer an additional 5 min. The thrombus 
was allowed to mature A)r an additional 30 min prior to administration of the study 
formulation. The presence of an occlusive thrombus was conArmed in three ways: 1) the 
cyanotic appearance of the leA ventricle; 2) the lack of Aow demonstrated with the 
Doppler Aow probe; and 3) S-T-segment changes in the ECG. A mean of 2.7 ± 0.3 
infections were required to achieve thrombosis with saline and did not differ signiAcanAy 
between treatment groups.
Dogs were randomly selected to receive one of Ave infused formulations: saline; 
blank microcapsules (6 gm, BLANK); Aee SK (FREE SK, 240,000 lU); Aee SK/blank 
microcapsules (FREE SK + BLANK, 240,000 lU); and MESK (240,000 lU). Each 
preparaAon was separated into 4 vials with the contents of each vial suspended in 8 mL 
normal saline and administered consecuAvely for a total infused volume of 32 mL. An 
iniAal bolus of 20,000 lU in the Arst minute preceded a constant infusion of the 
remaining formulaAon over a 2 h period. Animals were observed for 4 h following the 
iiAAaAon of infusion. Reperfusion was documented by a recovery of leA descending 
coronary arterial Aow. Sustained reperfusion was deAned as Aow returning to at least 
20% of the baseline Aow for the remainder of the experiment without another occlusion 
event.
84
Blood loss from the injury sites (femoral vein exposure, chest cavity exposure, 
and thrombin injection site in the coronary artery) was collected starting with the 
administration of the study formulation by cotton sponges and measured gravimetrically. 
At the conclusion of the experiment, 2 mL of blood was collected in 3.8% (wt/wt) 
sodium citrate at a ratio of 9:1 bloodianticoagulant and immediately centrifuged to obtain 
plasma. Samples were frozen for later determination of plasma fibrinogen with a 
commercial assay (Sigma Chemical). Clotting times were obtained in duplicate for each 
sample and compared to a standard curve of human plasma.
At the conclusion of the experiment, the heart was removed and the left anterior 
descending coronary artery was dissected. Residual thrombus mass was determined 
gravimetrically. The heart was sectioned into 5-nun slices parallel to the AV groove and 
stained with triphenyltetrazolium chloride, a histological stain forming a brick-red 
precipitate in the presence of intracellular dehydrogenases, delineating vital myocardium. 
Infarcted myocardium was distinguished by the absence of staining. After storage 
overnight in 10% buffered formalin, infarcted tissue was separated from surviving 
myocardium with a scalpel blade and expressed as percentage of total left ventricular 
mass.
Statistics
Using the Student-Newman-Keuls Multiple Comparisons Test, p values < 0.05 
were considered significant. Unless otherwise stated, all results are expressed as mean 
± standard error.
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RESULTS
Encapsulation efficiency was determined with commercial assays both by the 
concentration of protein present in the microparticles as well as the activity of the protein. 
Recovery of materials in the formation of microparticles (PEG + SK + PVA) was 91 ±
1% (n=14). The efficiency of protein entrapment based on concentration was 64 ± 7 %. 
However, administration dosages were determined using the activity-based encapsulation 
efficiency test. Efficiency based on activity averaged 32 ± 2%. It is likely that SK 
activity is lost during the preparation process, a common observation when encapsulating 
proteins in microparticles using this method [65].
As expected, no reperfusion occurred by treatment with saline alone or blank 
microcapsules suspended in saline. MESK produced a significantly reduced mean initial 
reperfusion time of 24 ± 4 min compared to FREE SK (p<0.01) and FREE SK + BLANK 
(p<0.05) with similar mean reperfusion times of approximately 50 min (Figure 6.2). 
Sustained reperfusion time was defined as continuous flow through the once-occluded 
vessel of at least 20% of baseline for the remainder of the experiment. One MESK- 
treated animal did not reperfuse, while another did not achieve sustained reperfusion after 
an initial reperfusion time of 23 min. FREE SK reperfused 77% of those animals treated 
(11/14) Wiile FREE SK + BLANK resulted in a 92% reperfusion rate (12/13). 
Comparable dosages of MESK resulted in a significant reduction in the average time to
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Figure 6.2: Average initial and sustained reperfusion times for each treatment formulation. 
* p<0.05 vs. FREE SK; f  p<0.01 vs. FREE SK
achieve sustained reperfusion (29 ± 4 min vs. 68 ± 7 min for FREE SK and 83 ± 18 min 
for FREE SK + BLANK).
Initial and sustained reperfusion times were comparable for MESK as a result of 
the reduced frequency of reocclusion episodes (Table 6.1). MESK-treated canines 
experienced 1.0 ± 0.5 reocclusion events per animal during the 4 h period fbllowing 
treatment onset, while FREE SK- and FREE SK + BLANK-treated animals demonstrated 
reocclusion more frequently. Occluded coronary vessels lysed with MESK tended to stay 
open, while those vessels lysed with either FREE SK formulation experienced more 
episodes of reocclusion fbllowing initial restoration of flow (Table 6.1).
Infarct mass is expressed as a percentage of total left ventricular (LV) mass 
(Table 6.1). Controls of blank microcapsules added to either saline or FREE SK yielded 
infarct mass equal to the respective preparations without microcapsules. The infusion of 
any SK formulation demonstrated significant decreases in infarcted tissue, with both 
FREE SK fbrmulations producing relatively equal infarct values and MESK resulting in a 
nearly 50% reduction in infarct mass compared to FREE SK fbrmulations (p<0.05 vs. 
FREE SK/FREE SK + BLANK).
Bleeding is known to be a common problem with streptokinase due to the 
systemic lytic state invoked by the agent. Additionally, circulating residual plasmin 
degrades several plasma proteins, particularly fibrinogen. Factor V, and Factor Vlll [8].
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Residual Clot 
Mass [mg]
Reocclusion
Episodes
Infarct Mass 
[% LV]
Blood Loss 
[g]
Fibrinogen
[pmol/L]
30.2 + 4.1 (14) — 19.2 ±2.9 (13) 4.7 ± 1.4(4) 14.4 ±0.8 (5)
38.0 ±5.5 (13) — 19.1 ±2.2 (13) 8.9 ± 4.7 (4) 14.6 ± 0.5 (4)
12.8 ±2.3 (14) 2.0 ±0.4 (14) 12.3 ±2.4 (13) 36.9 ± 7.6 (4) 6.7 ± 0.4 (4)
9.5 ±3.8 (13) 2.9 ± 1.0(13) 12.2 ±2.0 (13) 52.6 ± 18.9 (5) 5.0 ± 0.3 (4)
7.2 ±3.2 (13) 1.0 ±0.5 (13) 6.5 ± 1.5(12) 11.5 ±6.0 (3) 12.4 ± 1.4(4)
Table 6.1: Residual clot mass, reocclusion episodes, infarct mass, and bleeding complications in
a canine model of coronarv thrombosis.
To quantify bleeding complications accompanying each agent, blood released 6om the 
injury sites after the initiation of drug therapy was absorbed by multiple sponges and 
weighed (Table 6.1). Animals treated with saline alone or blank microcapsules 
demonstrated a lack of bleeding 6om all sites of injury. As expected, animals receiving 
FREE SK or FREE SK + BLANK showed more bleeding than saline-treated dogs. In 
stark contrast, MESK treatment resulted in significantly reduced blood loss compared to 
FREE SK. As another means to quantify bleeding potential, plasma fibrinogen levels 
were examined for each treatment modality (Table 6.1). Dramatic drops in circulating 
Ebrinogen levels determined in non-SK controls were observed only with FREE SK 
formulations (60% on average), while MESK-animals retained significantly higher levels 
of the clotting factor (only 15% drop). Graphical comparisons of blood loss and 
fibrinogen levels are presented in Figure 6.3.
DISCUSSION
Rapid restoration of blood flow to ischemic tissue is paramount to improve 
survival and organ function. Although multiple techniques are available to remove the 
occlusive thrombus and restore flow, the administration of plasminogen activators is a 
practical and effective method that can be utilized despite the presence of highly trained 
personnel and equipment.
The early open artery hypothesis proposes that faster reperfusion results in 
increased salvage of ischemic myocardium at risk for infarction, improved preservation 
of ventricular function, and improved survival. The extent of myocardial infarction in a 
canine model has been directly linked to the duration of occlusion [74]. Newby and
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Figure 6.3: Bleeding complications for grouped thrombolytic formulations comparing 
blood loss (top) and fibrinogen concentrations relative to saline (bottom).
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others have demonstrated that increased mortality is observed clinically for every hour of 
treatment delay [75, 91,94,95]. Therefore, it is desirable to affect reperfiision therapy as 
soon as possible and restore blood flow to deprived tissues.
Drug encapsulation systems have typically been applied for controlled or timed 
release, targeted delivery of agent, and/or mitigation of toxic side effects [63]. In the case 
of plasminogen activators, drug delivery vehicles block premature reaction to reduce 
systemic activation and depletion of key components of the fibrinolytic system while also 
accelerating reperfusion and increasing the extent of thrombus removal. Encapsulated 
plasminogen activators clearly show promise both in enhancing performance and in 
addressing concerns related to their underutilization. Data &om animal models confirm 
maintained fibrinogen levels, reduced blood loss, and fewer incidences of reocclusion.
In addition, encapsulation theoretically tends toward favoring convective delivery 
of agent over diffusion, so that (say) a blocked coronary artery should receive preferential 
delivery over a hemostatic plug in a small vessel wall or blocked capillary. Dissolution 
of hemostatic plugs is a highly diffusion dependent phenomena. This favoring of 
convection over diffusion can be realized by examining the Mass Flux Equation:
This equation shows that the flux of a chemical species (NA) generally depends on 
diffusion (-D^g V Q )  and convection Encapsulation decreases diffusivity
to the benefit of convective sites. The reduction in diffusivity can be appreciated from 
the Stokes-Einstein equation:
jtr
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where kT indicates the native thermal energy, r represents the size of the species and pg 
represents the viscous resistance to motion. It is seen that increases in the species radius 
decrease the diffusivity of the agent. Encapsulation of streptokinase increases its radius 
by several orders of magnitude (hom 3 to 800 nm with this formulation). Sites with 
significant convection, such as an occlusion in a coronary artery near a bifurcation, 
should be favored over an occluded capillary or a hemostatic plug on a vessel wall as the 
diffusivity is greatly reduced. Possible synergism between molecular advances in 
plasminogen activators and drug delivery systems could help these agents realize their 
potential for rapid intervention in cardiovascular crises.
In the present study, the intravenous infusion of MESK resulted in a greater than 
50% reduction in the time required to achieve sustained reperfiision (Figure 6.2) 
accompanied by a reduction in the incidences of reocclusion (Table 6.1). Reocclusion is 
a common phenomenon with Gbrinolytic agents that undoubtedly affects the level of 
infarct and mortality. Faster and more complete reperfusion also translates into smaller 
residual clot masses in the coronary artery. A smaller residual thrombus should act to 
reduce shear stress levels and the incidence of reocclusion.
More rapid reperfusion and fewer reocclusion events translate to less loss of 
myocardium. A relatively consistent infarct size (approximately 19% of LV mass) is 
produced in this model when thrombolytic treatment is not administered (Table 6.1). 
Reperfiision following FREE SK or FREE SK + BLANK administration reduced infarct 
size to approximately 12% of LV mass. The more rapid reperfiision observed with a 
comparable dosage of MESK further reduced the infarct size to 6.5%. While larger 
reductions in infarct size have been observed under conditions of more aggressive
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thrombolytic therapy [93], this study demonstrates that increased myocardial salvage may 
be achieved with an encapsulated fibrinolytic formulation without additional bleeding 
risk.
The threat of uncontrolled hemorrhaging is always a concern when using 
plasminogen activators because clotting function is often compromised by the depletion 
of circulating fibrinogen levels subsequent to their administration [9] In particular, 
streptokinase, a relatively non-specific agent, activates both clot-bound and circulating 
plasminogen indiscriminately. In this canine model, each of the three SK formulations 
depleted circulating fibrinogen when samples were taken at the conclusion of the 
experiment (Figure 6.3, bottom). However, MESK maintained higher fibrinogen 
concentrations at mean values of 12.4 ±1.4 pmol/L (420 ± 47 mg/dl) compared to 5.9 ±
0.4 pmol/L (199 ± 12 mg/dl) for the two FREE SK-fbrmulations (p<0.001). Li found 
similarly that utilizing liposomal encapsulated urokinase led to higher fibrinogen 
concentrations than in canines treated with an identical dose of free urokinase [7.4 ± 0.2 
pmol/L (250 ± 5 mg/dL) versus 4.7 ± 0.1 pmol/L (160 ± 4 mg/dL), respectively, p<0.01] 
[23]. By reducing the total exposure time of streptokinase to circulating plasma proteins 
through sequestration in microcapsules, encapsulation avoids the systemic depletion of 
fibrinogen. The beneSt of maintaining higher fibrinogen levels during thrombolytic 
therapy can be seen in the mass of blood lost throughout the experiment with each 
formulation (Figure 6.3, top). The infusion of MESK resulted in blood loss comparable 
to that observed without fibrinolytic treatment (11.5 ± 6.0 gm), while the administration 
of FREE SK-fbrmulations demonstrated significantly increased bleeding (45.6 ± 13.9 
gm, p<0.05).
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Liposomal encapsulated Gbrinolytic agents have demonstrated enhanced 
thrombolysis over &eely infused agents in vivo and in vitro with faster reperfusion times 
and reduced clot masses [22-25, 70] Issues of limited stability and prolonged 
preparation time, however, limit their commercial appeal as thrombolytic agents. The 
use of polymer-encapsulated streptokinase has now produced comparable results to those 
observed with liposomal encapsulation in an identical in vivo model [22] as well as 
additional positive findings on infarct size, reocclusion, and bleeding. Unlike aqueous 
liposomal formulations, this preparation has an extended shelf life. It has been observed 
that these microparticles retain original levels of activity with storage at room 
temperature for at least one year.
Compared to FREE SK, MESK improved thrombolysis for each endpoint in this 
study. MESK produced faster initial and sustained reperfusion times, reduced residual 
clot masses, fewer reocclusion episodes, smaller infarct mass, and reduced bleeding 
complications. Aggressive therapy in a clinical setting, made possible with encapsulated 
thrombolytic agents, could result in greater myocardial salvage.
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CONCLUSIONS
CHAPTER 7
Current treatment for patients presenting with dramatically reduced blood flow to 
tissue due to occlusive thrombi is less than optimal. Although several methods are 
available for recanalization of the blocked vessel, each has drawbacks that limit their use 
and ultimately deprives the patient of an optimal chance of full recovery. Angioplasty, 
although effective, is not widely available. Additionally, time-consuming screening and 
a specialized environment is required. Plasminogen activators are widely available for 
use, but there are issues with uncontrolled hemorrhaging and arriving for treatment 
during the prescribed window. It is widely accepted that, due to the ease of 
administration, thrombolysis could be more effective if used for all eligible patients. 
Patient arrival outside the treatment window is a contraindication for thrombolysis. 
Faster clot lysis with encapsulated agents could widen the treatment window and allow 
for more patients to receive thrombolytic therapy. Encapsulation of plasminogen 
activators has previously shown efficacy in numerous models to lyse occlusive thrombi 
more effectively than identical concentrations of free plasminogen activators. Despite
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varying models and agents, one theme is consistent throughout: encapsulated agents 
digest thrombi faster.
Previous in vivo studies utilizing liposomal encapsulated agents demonstrated 
faster reperfiision times with smaller residual clot masses compared to free agents. More 
complete clot digestion reduces the potential for restenosis or embolization. Despite the 
improvement over free activators, liposomal encapsulated activators have been slow to 
reach the clinic due to inherent difficulties in preparation and long-term stability. For this 
reason, a polymer encapsulated plasminogen activator has been investigated for its 
potential as a fibrinolytic formulation. As a solid dosage form, microencapsulated 
plasminogen activators possess extended storage potential that should improve the 
commercial appeal of this agent.
In this study, administration of MESK during in vivo experiments using a rabbit 
model of carotid thrombosis to approximate stroke and a canine model of coronary 
thrombosis as an approximation of myocardial infarction have each clearly demonstrated 
thrombolytic superiority over identical dosages of free streptokinase. Liposomal 
encapsulated streptokinase was also significantly better than free streptokinase in the 
rabbit model. Improved lysis capability was demonstrated by MESK in vitro as well. 
Based on the results of three occlusive models in this study (1 in vitro, 2 in vivo) along 
with studies performed by other laboratories worldwide, it should be evident that 
encapsulated plasminogen activators are more effective than free plasminogen activators.
In vitro studies have helped determine the mechanism of clot lysis with MESK.
As seen in microscopic images, clot digestion occurs very differently with MESK than 
FREE SK. While FREE SK tends to bind to the leading edge and promote localized
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reactions at the surface, MESK is able to penetrate the clot front so as to more effectively 
distribute the encapsulated streptokinase. With improved spatial distribution of 
streptokinase comes distributed intraclot thrombolysis, and therefore faster and more 
complete clot digestion.
Administrations of MESK in two in vivo models have provided strikingly 
different results than 6ee streptokinase. In the rabbit model of carotid thrombosis, 
reperfusion times and residual clot masses were dramatically reduced while a greater 
return of flow was observed. More extensive studies in a canine model of coronary 
thrombosis returned significant reductions in reperfusion time, along viith a host of other 
improved endpoints such as reduced bleeding, fewer reocclusion events, and decreased 
infarct size.
Despite the promising results achieved with encapsulated streptokinase, the 
microencapsulation of other plasminogen activators must now be explored. The 
reputation of streptokinase has become sullied over the years as an agent that results in 
uncontrollable bleeding with no true upside. In reality, it is the systemic degradation of 
fibrinogen that might be responsible for limiting the restenosis events so often reported 
with other plasminogen activators. The comparison of MESK to other microencapsulated 
agents is a question that arises whenever this research is presented, and the studies must 
be performed in order to answer this inquiry. More fibrin-specific agents such as 
alteplase or tenecteplase should be encapsulated to contrast results with that of 
streptokinase, a plasminogen activator with relatively little fibrin specificity.
As mentioned in Chapter 2, there have been recent studies describing the 
pegylation of plasminogen activators to increase circulation time and half-life. However,
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the thrombolytic potential of these formulations have not been examined. As 
polyethylene glycol is known to resist protein adsorption, it would be prudent to pegylate 
streptokinase and test its efBcacy using confbcal microscopy. This series of experiments 
could bolster the evidence of improved transport to the interior of the clot.
While 10,000 and 20,000 MW polyethylene glycol has shown promise for this 
application, other polymers should be examined that might provide greater improvement. 
For example, natural polymers such as dextran or hyaluronic acid which possess high 
water-solubility could be comparable with fewer physiological limitations. Copolymers 
of polyethylene glycol with polyethylene oxide might also provide greater control over 
release rate and further increase circulation times.
Although the current administration of MESK has demonstrated significant 
benefits, other administration methods should be investigated in future studies. For 
instance, a bolus infusion of a mixture of smaller and larger microparticles would provide 
a range of release rates once in the circulation while limiting the infusion to a single 
infusion task not requiring constant supervision. This undoubtedly would limit potential 
administration errors by clinical personnel which could result in untimely and unexpected 
deaths. Perhaps more importantly, the examination of administration regiments could 
demonstrate that a significantly reduced dosage of MESK is required to effectively 
restore and maintain vessel patency.
Results &om the numerical model demonstrate the tremendous effect that drug 
release rate has on clot lysis. Release rate, among other properties, can easily be 
manipulated by varying production parameters while using the double emulsion
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technique. Optimization of the production process should be investigated as a means to 
enhance clot lysis with MESK.
In conclusion, the infusion of encapsulated streptokinase for treatment of 
occlusion is superior to &ee streptokinase, as shown in two in vivo models, an in vitro 
model, and a numerical simulation. MESK restores flow faster, more completely, and 
safer than FREE SK. Considering the mechanism for efficacy, it is not a leap to believe 
that comparable results could be obtained with other plasminogen activators.
Comparable results with another agent such as t-PA or the newer tenecteplase could vault 
this technology to the clinical setting.
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APPENDIX A 
DESCRIPTION OF ASSAY TECHNIQUES
Pierce BCA (Bicinchoninic Acid) Protein Assay Protocol
Dissolve 10 mg of each sample in 1.0 mL of water in microcentrifhge tubes. Place in 
re&igerator until ready to use.
Prepare a fresh set of protein standards by diluting a 2.0 mg/mL Albumin (Alb) stock in 
the same diluent as your sample (i.e. phosphate buffered saline should be used as diluent 
when dissolving sample as well as standards). A list of standard dilutions follows below:
Final Alb Concentration Volume of Alb to add Volume of Diluent to Add
2.0 mg/mL 300 pL (stock) 0 pL
1.0 mg/mL (A) 325 pL (stock) 325 pL
0.5 mg/mL (B) 325 pL (A) 325 pL
0.25 mg/mL (C) 325 pL (B) 325 pL
0.125 mg/mL (D) 325 pL (C) 325 pL
0.025 mg/mL (E) 100 pL (D) 400 pL
0.0 mg/mL 0 pL 300 pL
Take care to mix each tube sufficiently prior to using it in a subsequent dilution. In order
to obtain 325 pL, it is suggested to pipette 2 x 100 pL, then 2 x 62.5 pL. This procedure
can be carried out with the white Eppendorff pipette only. This should allow for more
consistent results by not switching between instruments.
Prepare fresh BCA Working Reagent (WR) by mixing 50 parts of BCA Reagent A with 1 
part of BCA Reagent B. Prepare sufficient volume of WR based upon the number of 
tests to be done. Each test tube sample requires 2.0 mL of the WR. For example, if you
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have 12 samples (including standards), you will need 24 mL of WR. Therefore, mix 25 
mL of Reagent A with 0.5 mL of Reagent B.
Label disposable glass test tubes with the appropriate concentration of standard or 
identity of sample. Add 2.0 mL of the WR to each tube. Use the purple-plunger pipette 
(200-1000 pL) and pipette 4 x 500 pL in order to prevent excessive uptake. Add 100 pL 
of each standard and sample to the appropriately labeled test tube. Mix well with vortex 
mixer. Place tubes in test tube rack in incubator at 37°C for 30 minutes. Turnon 
spectrophotometer in D212 to a wavelength of 562 nm.
Remove tubes and allow cooling to room temperature ( -  5 minutes). Measure the 
absorbance at 562 nm of each tube vs. a water reference. ALL readings must be 
complete within 10 minutes to ensure continuity of the results.
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Protocol for Helena Laboratories Chrom-Z Plasminogen Assay 
(Activity Test)
Dissolve 5 mg of sample in 1.0 mL water. Place in refrigerator until ready to use. 
Dissolve 30 mg of Blank MESK in 6 mL DI water for use in standard curve preparation 
(polymer solution).
To 1.0 mL of PLG-buffer stock (green-capped vial), add 9.0 mL of DI water. Mix well. 
Prgpwg
Dissolve the stock (purple-capped vial) in 1.0 mL water. Mix well. First prepare a 100% 
dilution, then a 50% dilution.
100% SARP: Mix 100 pL stock + 500 pL PLG-buffer.
50% SARP: Mix 200 pL of the 100% SARP + 200 pL PLG buffer 
Place in refrigerator until ready to use.
500 lU/mL: 35 pL of 10,000 lU/mL SK + 665 pL diluent 
400 lU/mL: 320 pL of 500 lU/mL + 80 pL diluent 
300 lU/mL: 120 pL of 500 lU/mL + 80 pL diluent 
200 lU/mL: 200 pL of 400 lU/mL + 200 pL diluent 
100 lU/mL: 100 pL of 200 lU/mL + 100 pL diluent 
0 lU/mL: 300 pL diluent
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Prepare 2 sets of standards: one with water as diluent and another with the polymer 
solution as diluent.
frepore P/afoim vmZj
Add 2.0 mL distilled water and mix thoroughly. Refrigerate until use.
The kinetic analyses should be completed with a 96-well plate reader at 405 nm over 20 
minutes.
To each well, add:
1. 30 pL of PLG-buffer
2. 3 |iL of 50% SARP. Incubate at 37°C for 2-4 minutes.
3. 30 pL of standard or sample. Incubate at 37°C for 1 minute.
4. 30 pL of plasmin substrate quickly
5. Read at 405 nm for 20 min; automix once; Vmax OD, 86 readings
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Protocol for Sigma Chemical Fibrinogen Assay
rgoge/i/f -
1. Reconstitute Fibrinogen Reference with 1.0 mL DI water. Restopper vial and allow 
to stand until dissolution is complete. Invert gently to mix. DO NOT SHAKE.
2. Reconstitute Thrombin Reagent with 6.0 mL DI water. Restopper vial and allow to 
stand until dissolution is complete. Invert periodically. DO NOT SHAKE.
3. Imidazole Buffer is provided as a liquid and requires no preparation prior to use.
4. Store all reagents at 4°C until use.
1. Collect venous blood in 3.8% sodium citrate at a ratio of 9 parts blood to 1 part 
anticoagulant (1:10 ratio).
2. Isolate plasma by centrifuging at 2500 x g for 15 minutes. Test immediately or freeze 
at -80°C until use.
frgpwg ^ Armogg» r^ rg n cg  cfzWm/w—
Dilution Fibrinogen Reference (mL)
Imidazole Buffer 
(mL) Dilution Factor
1:5 0.5 2.0 2
1:10 0.5 of 1:5 dilution (Tube#l) 0.5 I
1:15 0.4 of 1:5 dilution 0.8 0.66
1:20 0.3 of 1:5 dilution 0.9 0.5
1:25 0.2 of 1:5 dilution 0.8 0.4
1:30 0.2 of 1:5 dilution 1.0 0.33
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Test plasmas are prepared by diluting plasma 1:10 with Imidazole BuHer in plastic tubes. 
Store dilutions at 4°C.
rejfrng—
1. Reconstitute Thrombin reagent and maintain at room temperature during testing.
2. To plastic tube, add 0.2 mL of the diluted plasma sample.
3. Incubate 1-3 min at 37°C (not longer than 5 min).
4. Following incubation, rapidly expel 0.1 mL of Thrombin reagent into the tube while 
simultaneously starting a timer. Record clotting time in seconds.
5. Repeat each sample and take the average clotting time.
6. Extrapolate concentration &om calibration curve.
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APPENDIX B 
DERIVATION OF NUMERICAL SIMULATION
Key assumptions:
1. The concentrations of clot-bound plasminogen and antiplasmin remain constant 
within the clot, as any degraded clot-bound plasminogen is instantaneously 
replaced by plasminogen from the flowing fluid (Blinc et al., 1991).
2. Structural properties of the thrombus (i.e. porosity, permeability) do not change 
over time.
3. Velocity of interstitial flow is assumed constant (Blinc et al., 1991).
4. Diffusivity of each jGree species and MESK are uniform and constant throughout 
the clot (Bhnc et al., 1991). In other words, a constant particle size of MESK is 
assumed, and it will travel with the same velocity as the fluid and not be sieved 
out through the clot.
5. Adsorption and desorption rate constants are constant for each species throughout 
clot digestion.
6. Streptokinase is either encapsulated or released, but there is no intermediate 
complex that might have lingering PEG molecules attached to the protein.
7. Release of streptokinase from the microparticles follows the Hixson-Crowell 
model.
8. Each node within the clot is digested when the fibrin concentration drops to 2/3 of 
its initial value [3.882 pM] (Blinc et al., 1991).
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Derivation of Model Parameters:
DIFFUSIVITY
An average diffusion coefGcient is assumed for MESK (D MESK ) by using the 
Stokes-Einstein relationship for diffusivity of a particle within a fluid:
D = k T where k*T indicates the thermal energy, r is the size of theÔTtru species, and ^represents the viscous resistance to motion.
Upon assuming a constant diffusivity of free species of 3e-6 cm ^/min [&om Diamond's 
numerous publications and knowing the radius of streptokinase (3.6 nm) [Damaschun et 
al., 1992; Wilkins et al., 1999] and assuming an average particle radius based on particle 
size measurements in our laboratory (0.2 p,m; data not shown), a ratio of the equations is 
used to calculate the diffusivity of MESK.
Dgj^ — 3 X 10-  6 cm k T
min 671 p'(3.6nm)
D
cm k T
MESK min 6 71 p(200nm)
FLUID VELOCITY
^MESK -  5 X 10
8 cm
nun
An average fluid velocity is determined based upon flowrate data collected when 
digesting thrombi formed of plasma and thrombin in glass capillary tubes (Chapter 4). 
The flow (cm 3) was determined for multiple time steps, and averaged over the time of 
clot digestion. Velocity was then calculated by dividing the average flowrate by the 
cross-sectional area of the pipet. The result is shown below.
Q
A
V=
FREE SK
0.Ô2678 cm'^S 
Ô.282743
0 .0 9 4 7 1 5  cm /m in
Q = 
A =
V =
MESK
d.Ô226Ô4icm''3 
0.282743 cm''2
0 . 0 7 9 9 4 6  c m / s e c
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POROSITY OF THROMBUS
A value for an average thrombus porosity velocity was selected from Anand, Wu, and 
Diamond's paper [1995] in which the overall porosity for fibrin gels is greater than 0.99. 
Diamond et al. have consistently used e = V vom/V-roTy^^ = 0.9928.
KINETICS OF ADSORPTION AND DESORPTION
Values for the kinetics of adsorption and desorption were taken from several 
publications and hypothesized. The kinetic constants are listed in the table in Chapter 6. 
For the values of adsorption and desorption of MESK, they are merely speculated. As 
polyethylene glycol is known to resist protein adsorption, it is proposed that the rates of 
adsorption are at least 2 orders of magnitude smaller than the 6ee streptokinase- 
plasminogen complex.
ESTIMATE OF MICROPARTICLE DISSOLUTION RATE
Based on numerous experiments monitoring the release rate of a model protein (bovine 
serum albumin) versus time for multiple preparation techniques, the Hixon-Crowell 
model was selected as the best empirical fit of the data. An estimate of the polymer 
dissolution/drug release rate is obtained by plotting the cubic root of the fraction of 
released drug against time, and the slope represents the release rate.
Determination of Release Rate
C?
0.9
0.8
y -  .0.0179X + 0.967 
-  0.94270.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0 10 3020 40 6050
T im e  (m in )
The value for K to 0.022 m i n w a s  then increased to better approximate the "average" 
release rate.
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FLUID PHASE FREE and  BOUND SK:
-CSK^  " DSK^ -^CsK^ - V _at 1.BX A B y St
+ l-kl'CSK*' cpLG^  + Wl CSKPLO^
Initial Condition:
CsK » Ci for all x at t=0 
Boundary conditions:
0 ^ _____„  SK  in plasma rises rapidly in ju s t 5-10 min and then levels off more or less (Tuliani)
Left side: — Cj k  = 0
0X A ssum e C g ^s f x=0 is constant.
Right side: — Cs k - 0
0X
s  0 A ssum e no interaction of SK alone w ith fibrini
at
FLUID PHASE AND BOUND PLASMINOGEN:
-Cpui*' =Dpuî*^  -?-—CpLG^ - 
St 01^
fs f ll  ^1 — b'\ 9 _ bV -CpLG - ----- -CpLG
. lax )_ I  B jg t
■ ((-M'CsK^ 'CpijG^  + kMl 'CsKPCS^ ~ Iq CskPUJ^  Cplg*’))
Initial Condition:
CPLO^ = 2-2
Boundary conditions: 
None required.
Assume that the concentration of plasminogen within the thrombus does not change with time since the activated 
plasminogen in the thrombus is instantaneously replaced by flowing blood from the blood plasma pool. Therefore, this 
equation does not need to be included in the solution (Zidansek and Blinc, 1991).
-CpLG =0
Bt
CPU>'^  = 47.618
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FLUID PHASE AND BOUND SK-PLASMINOGEN COMPLEX:
-CSKPLO
,8%
-—- | -CSKPLG^ + (kl CsK*' cpua^  - kjVirCsKPLO^ - l^  CsKPLG^ CpUj*')
E y Bt
Initial Condition:
CSKPLG = 0 k r  all » at 1=0 
Boundary conditions:
Left side: Csk p lg  = Cj k  at x=D for all I Assume equilibrium with high concentration of SK at x=0
Right side: —Cs k PLG "  0
Bx
®SKPLG = — 0 .2 6 - !^
monomer L
-CSKPm^  = i'ADS^ ^^  ^CSKPLG*' (9SKPlJG*’ - CsKPLG^) " I'DES^’^ ^  CskpDs’’  ^'
FLUID PHASE and BOUND PLASMIN :
-CpLM^  = DpLM^ -^ CpLM^  -
St Sx"^
f a .  0 1 01 ■“ 8 9 bV- -C p L M - ------- -C pL M
iBx n A '
■ (iQ-CsKPIJG^' cpijG*' - It3-CPLM^ + iy CpLM*" Cfbn)
Initial Condition:
CpLM = 0 fot all K at t=G 
Boundary conditions:
Left side: CpLM = CSKPLG at x=0 for all t
Right side: —Cp l m  *  0
Sx
B „  b , PLM _ r { .  b _ b'l , PLM _ b -CpLM = kADS CpLM \GpLM " CpLM j ~ l^ lES CpLM 
0t
monomer L 
k A B S ^ ^  = 03e -  3
L s
PLM , 1kp)ES = 5 .4 3 d e - 3 -
BOUND FIBRIN CONCENTRATION:
Using 4th equation above:
-CpEN = -k4'CpLM  ^CpBN 
et
C F B N ^ = ) ^ ^
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APPENDIX C 
FORTRAN CODES 
Digestion of plasma clots using &ee streptokinase:
PROGRAM FREESK_1
c Programmer: J. Kent Leach
c Date: June 26, 2003
0  Location: University of Oklahoma School of Chemical Engineering
c and Materials Science
c The purpose of this program is to model the digestion of thrombi
c formed of plasma and thrombin that are treated with streptokinase,
c The movement of various moieities will be followed
c with a standard convection-diffusion equation for each species, along
c with terms for reactions and the prediction of absorption of
c said species to the thrombus.
c SKf=streptokinase in fluid phase; PLGf=plasminogen in fluid phase;
c PLGb=plasminogen in solid phase; SKPLGf=streptokinase/plasminogen complex in
c fluid phase; SKPLGb= streptokinase/plasminogen complex in solid phase;
c PLMf=plasmin in fluid phase; PLMb=plasmin in solid phase;
c FBN=fibrin; PLMAP= plasmin inactivated by alpha-2 antiplasmin
c  FDP=fibrin degradation products
c Reaction schem e (including constants)
c
c SK + PLG <— > SKPLG (K1. KM1 )
C SKPLG + PLG —> PLM + SKPLG (K2)
c PLM > PLMAP (K3)
c PLM + FBN —> PLM + FOP (K4)
IMPLICIT REAL*8(A-H,L-Z)
REAL K1 ,KM1,K2,KM2,K3,K4.KaSKPLGf,KdSKPLGf,KaPLMf,KdPLMf
PARAMETER (M=200,N=20000)
c Setting up the arrays for all concentrations of species
DIMENSION SKf(0:201,0:20001),SKPLGf(0:201,0:20001),
$ SKPLGb(0:201,0:20001),PLGf(0:201,0:20001),
$ PLMf(0:201,0:20001),PLMb(0:201,0:20001),
$ FBN(0:201,0:20001)
Lclot=3.0d0 IThe length of the clot is 3.0 cm
dx=Lclot/M (Distance in x-direction is 0.02 cm
dt=1.66667d-3 (Time difference is 0.1 sec  (1.67E-3 MIN)
Iambda=dt/(dx**2.0d0) Istability quotient
D=3.0d-6 (Diffusion coefficient of free species
c assumed constant at 3e-06 cm''2/min
vx=0.095d0 (Fluid velocity considered constant at 0.095 cm/min
EPS=0.9928d0 (Void fraction (porosity) of thrombus held constant
c Rate constants for reactions
K1=60.0d0 (min*-1
KM1=1.8d-3 (min*-1
K2=22.02d0 lmin*-1
K3=0.24d0 lmin*-1
K4=1500.0d0 !min*-1
125
PLGb=47.618dO !umol/L;bound [PLG] remains constant
KaSKPLGf=5.748d-3 !umol/L*min;Rate of adsorption of SKPLGf to fibrin
KdSKPLGf=3.9948d-3 !min^-1;Rate of desorption of SKPLGf from fibrin
ThetaSKPLGb=0.39 !umol/L;concentration of sites avaiiable for SKPLGf
KaPLMf=0.03d0 lumol/L'min; Rate of adsorption of PLMf to fibrin
KdPLMf=3.264d-3 lmin^-1 ; Rate of desorption of PLMf to fibrin
ThetaPLMb=1 .OdO lumol/L; concentration of sites available for PLMf
INITIALIZE THE MATRICES WITH VALUES FROM INITIAL CONDITIONS 
DO 1 1=0,M
SKf(0,0)=0.76d0 !umol/L;initial streptokinase concentration 
CONTINUE I bound to leading edge
DO 2 1=0,M
SKPLGf(0,0)=SKf(0,0) !umol/L;SKPLG in equilibrium with SK 
CONTINUE
DO 3 l=0,M
PLGf(l,0)=2.2d0 !umol/L;initial plasma plasminogen concentration 
CONTINUE
DO 4 l=0,M
PLMf(l,0)=O.OdO lumol/L;no plasmin initially present until 
CONTINUE ! conversion from plasminogen by SKPLG
DO 5 1=0,M
PLMb(l,0)=0.0dC
CONTINUE
DO 6 1=0,M
FBN(l,0)=5.823d0 lumol/L; initial concentration of fibrin in clot 
CONTINUE
c  Begin time (J) and position (I) iterations.
39 DO 40 J=0,N
TIME=J'dt
IF Q.LE.N) THEN
DO 50 i=0,M
IF (i.EQ.O) THEN 
GOTO 11 
ELSE IF (i.GT.O) THEN 
GOTO 15 
ELSE IF (i.EQ.M) THEN 
GOTO 20
END IF
c Fill matrix with values of concentration for each species based on the convection-diffusion
c equation with reaction and absorption influences.
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c For streptokinase in the fluid phase (SKf):
15 SKf(i j+1)= SKf(i j )  + dt'D*0.5d0*((SKf(i+1 j+1)-2.0d0'SKf(lj+1)
$ +SKf(i-1j+1))/(dx"2.0dO)
$ +(SKf(i+1 ,j)-2.0dO*SKf(i j)+SKf(i.1 j))/(dx"2.0d0))
$ -dr(vxXSKf(i+1.j)-SKf(i'1j))/(2.0dO'dx))
$ -dt*(((1.0dO-EPS)/EPS)*0.0)
$ +dr(-KrSKf(lj)TLGf(ij) + KM1*SKPLGf(i.j))
c For plasminogen in the fluid phase (PLGf):
PLGf(i,j+1)= PLGf(lj) + drD*0.5d0*((PLGf(i+1,j+1)-2.Od0*PLGf(i,j+1)
$ + PLGf(i-1 j+1 ))/(dx"*2.0d0)
$ + (PLGf(i+1 j)-2.0d0*PLGf(i.j)+PLGf(i-1 ,j))/(dx**2.0d0))
$ - dt'(vx*(PLGf(i+1 ,j)-PLGf(i-1 J))/(2.0d0*dx))
$ -dt*(((1.0d0-EPS)/EPS)*0.0)
$ + dt*(-K1*SKf(ij)*PLGf(l,j) + KM1*SKPLGf(i,j)
$ . K2'PLGf(ij)*SKPLGf(i,D)
c For streptokinase-plasminogen complex in the fluid phase (SKPLGf):
SKPLGf(i,j+1)= SKPLGf(ij) + drD*0.5d0*((SKPLGf(i+1,j+1)
$ - 2.0d0'SKPLGf(iJ+1 ) + SKPLGf(i-1 J+1 ))/(dx*'2.0d0)
$ + (SKPLGf(i+1 j)-2.0dO'SKPLGf(ij)
$ +SKPLGf(i-1,D)/(d)r2.0d0))
$ - dt*(vx*(SKPLGf(i+1 ,j)-SKPLGf(i-1 J))/(2.0d0*dx))
$ - dt'(((1 .OdO-EPS)/EPS)*SKPLGb(i,j))
$ +dt*(KrSKf(ij)*PLGf(ij)
$ - KM1*SKPLGf(i,j)
$ - K2*PLGf(i,j)*SKPLGf(i,j))
c For plasmin in the fluid phase (PLMf):
16 PLMf(i,j+1)= PLMf(i j )  + dt*D*0.5d0*((PLMf(l+1 j+1)
$ - 2.0d0*PLMf(i j+1) + PLMf(i-1 j+1))/(dx"2.0d0)
$ +(PLMf(i+1j)-2.0d(TPLMf(ij)
$ + PLMf(i-1 j))/(dx**2.0d0))
$ - dt'(vx'(PLMf(i+1 j)-PLMf(i-1 ,j))/(2.0d0*dx))
$ - dt*(((1 .OdO - EPS)/EPS)*PLMb(ij))
$ + dt*(-K3*PLMf(ij) + K2TLGf(i j)'SKPLGf(i j))
c STREPTOKINASE IN THE FLUID PHASE
c Left boundary condition for SK in fluid phase
11 SKf(Oj+1)=SKf(Oj) + dt*D*0.5d0*((2.0d0*SKf(i+1j+1)-2.0d0
$ *SKf(ij+1))/(dx"2.0dO) +
$ (2.0d0*SKf(i+1 j)-2.0d0*SKf(i j))/(dx"2.0d0))
$ + dr(-K1*SKf(0,D'PLGf(0j) + KM1'SKPLGf(0j))
c PLASMINOGEN IN THE FLUID PHASE
c Left boundary condition for PLG in fluid phase
PLGf(0j+1) = PLGf(Oj) + dt*D*0.5d0*((2.0d0*PLGf(i+1 j+1 )-2.0d0 
$ *PLGf(ij+1))/(dx**2.0d0) +
$ (2.0d0'PLGf(i+1 j)-2.0d0*PLGf(i j))/(d)T2.0d0))
$ + dt*(-K1 'SKf(Oj)*PLGf(Oj) + KM1 *SKPLGf(0,j)
$ + -K2'SKPLGf(0 j)*PLGf(0,j))
c STREPTOKINASE/PLASMINOGEN COMPLEX IN THE FLUID PHASE
c Left boundary condition for SKPLG in the fluid phase
SKPLGf(0j+1)=SKf(0j)
c PLASMIN IN THE FLUID PHASE
c Left boundary condition for PLM in the fluid phase
PLMf(0j+1)= PLMf(1 j)
$ - dt*((1 0d0-EPS)/EPS)*PLMb(0 j)
$ + dt'(-K3'PLMf(M j)  + K2*PLGf(M j)'SKPLGf(M,j))
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c For plasmin in the solid phase (PLMb):
17 PLMb(i j+1)=  PLMb(ij)
$ + dt*(KaPLM*PLMf(ij)'(ThetaPLMb
$ - PLMb(ij)) - (KdPLMfPLMbdj)))
c For streptokinase-plasminogen complex in the solid phase (SKPLGb):
SKPLGb(i,j+1)= SKPLGb(i,D 
$ + dt*(KaSKPLGfSKPLGf(ij)
$ *(ThetaSKPLGb-SKPLGb(i,j))-KdSKPLGfSKPLGb(i,j))
20 IF (i.EQ.M) THEN
c STREPTOKINASE IN FLUID Right side (M):
SKf(M,j+1)= SKf(M,j) + dt'D'(O.5d0'(2.OdO*SKf(M-1 j+1)-2.0d0 
$ *SKf(MJ+1))/(dx*^.OdO)
$ + (2.0d0*SKf(M-1 ,i)-2.0d0*SKf(M.j))/(dx**2.0d0))
$ + dt'(-K1 *SKf(M j)'PLGf(M,j) + KM1 *SKPLGf(MJ))
c PLASMINOGEN IN FLUID Right side (M):
PLGf(MJ+1) = PLGf(M.j)
$ + drD'0.5d0*((2.0d0'PLGf(M-1 j+1 )-2.0d0
$ *PLGf(Mj+1))/(dx**2.0d0)
$ + (2.0d0'PLGf(M-1,j)-2.0d0'PLGf(M,j))/(dx**2.0d0))
$ + dr(-K1*SKf(M.j)*PLGf(Mj) + KM1'SKPLGf(Mj)
$ - K2'SKPLGf(Mj)'PLGf(Mj))
c STREPTOKINASE-PLASMINOGEN COMPLEX IN FLUID Right side (M):
SKPLGf(Mj+1)= SKPLGf(Mj) + dt*D*0.5dO'((2.0d0*SKPLGf(M-1 j+1)
$ - 2.0d0'SKPLGf(Mj+1))/(dx*^.0d0)
$ + (2.0d0*SKPLGf(M-1j)-2.0d0*SKPLGf(ij))/(dx**2.0d0))
$ - dt'((1 .OdO-EPS)/EPS)'SKPLGb(M j)
$ + dt*(KrSKf(M,j)*PLGf(Mj)-KM1*SKPLGf(Mj)
$ - K2'SKPLGf(M j)*PLGf(M,D)
c PLASMIN IN FLUID Right side (M):
PLMf(MJ+1)= PLMf(MJ) + dt*D*O.5dO*((2.Od0*PLMf(M-1j+1)
$ - 2.0d0'PLMf(M j+1))/(dx"2.0d0)
$ + (2.0d0*PLMf(M-1 j)-2.0d0'PLMf(ij))/(dx**2.0d0))
$ - ((1.0d0-EPS)/EPS)*PLMb(Mj)
$ + dt*(-K3'PLMf(Mj) + K2*PLGf(M,j)*SKPLGf(M j))
END IF
c FIBRIN IN THE SOLID PHASE (FBN):
18 FBN(lj+1)= FBN(ij) + dt*(-K4'PLMb(i.j)*FBN(ij))
write (*,*) ij
c Put the desired results in a file titled "CNResultsSK"
OPEN (unit=6,file='CNResultsSK.out’)
IF (SKf(i,j).LT.1.0d-10) THEN 
SKf(ij)=O.OdO
END IF
IF (SKPLGf(ij).LT.1.0d-10) THEN 
SKPLGf(lj)=O.OdO
END IF
IF (SKPLGb(ij).LT.I.Od-IO) THEN 
SKPLGb(ij)=O.OdO
END IF
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IF (PLGf(i.j).LT.1.0d-10) THEN 
PLGf(i,j)=O.OdO
END IF
IF (PLMf(l,j).LT.1.0d-10) THEN 
PLMf(ij)=O.OdO
END IF
IF (PLMb(ij).LT.1.0d-10) THEN 
PLMb(ij)=O.OdO
END IF
IF (FBN(lj).LT.3.882dO) THEN
FBN(i,j)=O.OdO
END IF
50 CONTINUE
END IF
WRITE (6,100) SKf(0:200,J) 
c WRITE (6,100) PLGf(0:200,j)
c WRITE (6,100) SKPLGf(0:200,i)
c WRITE (6,100) PLMf(0:200j)
c WRITE (6,100) PLMb(0:200,j)
c WRITE (6,100) FBN(0:200,j)
40 CONTINUE
100 FORMAT (e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4.e15.4,e15.4,e15.4,e15.4,e15.4,
$ e l  5.4,e15.4,e15.4,e15.4,e15.4,e15.4,e l  5.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e l 5.4,e l 5.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4.e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e l  5.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4.e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e l  5.4,e l  5 .4 ,e15.4,e l  5.4,e l  5.4,e l  5.4,e l  5.4,e l  5.4,e l  5.4,e l  5.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,
$ e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4,e15.4)
WRITE (*,*) "DONE"
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STOP
END PROGRAM FREESK 1
Digestion of plasma clots using microencapsulated streptokinase:
PROGRAM MESK_1
c Programmer: J. Kent Leach
c Date: July 10, 2003
c Location: University of Oklahoma School of Chemical Engineering
c and Materials Science
c The purpose of this program is to model the digestion of thrombi
c treated with microencapsulated streptokinase. Compared to free
c streptokinase, MESK has demonstrated in vitro improved distribution
c of clot lysis. The movement of various moieities will be followed
c with a standard convection-diffusion equation for each species, along
c with terms for reactions and the prediction of absorption of
c said species to the thrombus.
c SKf=streptokinase in fluid phase; PLGf=plasminogen in fluid phase;
c PLGb=plasminogen in solid phase; SKPLGf=streptokinase/plasminogen complex in
c fluid phase; SKPLGb= streptokinase/plasminogen complex in solid phase;
c PLMf=plasmin in fluid phase; PLMb=plasmin in solid phase;
c FBN=fibrin; PLMAP= plasmin inactivated by alpha-2 antiplasmin
c FDP=fibrin degradation products
c Reaction schem e (including constants)
c
c M ESK— > SK + PEG (Kdissolve)
c SK + PLG <—> SKPLG (K1, KM1)
c SKPLG + PLG —> PLM + SKPLG (K2)
c P LM  > PLMAP (K3)
c PLM + FBN —> PLM + FDP (K4)
IMPLICIT REAL'8(A-H,L-Z)
REAL K1 ,KM1 ,K2,KM2,K3,K4,KaSKPLGf,KdSKPLGf,KaPLMf,KdPLMf 
REAL KaMESKf.KdMESKf,Kdissolve 
PARAMETER (M=200,N=18000)
c Setting up the arrays for all concentrations of species
DIMENSION SKf(0:201,0:20001),SKPLGf(0:201.0:20001),
$ SKPLGb(0:201,0:20001),PLGf(0:201,0:20001),
$ PLMf(0:201,0:20001),PLMb(0:201,0:20001),
$ MESKf(0:201,0:20001),MESKb(0:201,0:20001),
$ FBN(0:201,0:20001)
Lclot=3.0d0 IThe length of the clot is 3.0 cm
dx=Lclot/M IDistance in x-direction is 0.02 cm
dt=1.66667d-3 ITime difference is 0.1 sec  (1.67E-3 MIN)
D=3.0d-6 [Diffusion coefficient of free species
c assumed constant at 3e-06 cm*2/min
lambda=D*dt/(dx**2.0d0) Istability quotient
DMESK=5.0d-8 [Average diffusion coefficient of microparticles 
c from Stokes-Einstein ratio (cm''2/min)
vx=0.08d0 [Fluid velocity considered constant at 0.08 cm/min
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EPS=0.9928d0 IVoid fraction (porosity) of thrombus held constant
Rate constants for reactions 
K1=60.0d0 !min''-1
KM1=1.8d-3 !min''-1
K2=22.02d0 !min^-1
K3=0.24d0 !min^1
K4=1500.0d0 !min*-1
Kdissolve=0.022d0 !min*-1
PLGb=47.618dO
KaSKPLGf=5.748d-3
KdSKPLGf=3.9948d-3
ThetaSKPLGb=0.39
!umol/L;bound [PLG] remains constant
!umol/L*min;Rate of adsorption of SKPLGf to fibrin 
lmin*-1 ;Rate of desorption of SKPLGf from fibrin 
!umol/L;concentration of sites available for SKPLGf
KaPLMf=0.03dO
KdPLMf=3.264d-3
ThetaPLMb=1.0d0
!umol/L*min; Rate of adsorption of PLMf to fibrin
!min*-1 ; Rate of desorption of PLMf to fibrin 
lumol/L; concentration of sites available for PLMf
KaMESKf=5.748d-5
KdMESKf=3.9948d-5
ThetaMESKb=0.39
!umol/L*min;Rate of adsorption of MESKf to fibrin 
!min''-1 ;Rate of desorption of MESKf from fibrin
lumol/L;concentration of sites available for SKPLGf
INITIALIZE THE MATRICES WITH VALUES FROM INITIAL CONDITIONS
DO 1 1=0,M
SKf(0,0)=1.38d-5
CONTINUE
DO 2 1=0,M
MESKf(0,0)=1.1d-3
CONTINUE
!umol/L;initial streptokinase concentration 
! bound to leading edge
lumol/L;initial PEG concentration
DO 3 1=0,M
SKPLGf(0,0)=SKf(0,0) !umol/L;SKPLG in equilibrium with SK 
CONTINUE
DO 4 1=0,M
PLGf(l,0)=2.2d0
CONTINUE
!umol/L;initial plasma plasminogen concentration
DO 5 l=0,M
PLMf(l,0)=0.0d0 !umol/L;no plasmin initially present until
CONTINUE I conversion from plasminogen by SKPLG
DO 6 l=0,M
PLMb(l,O)=O.0dO
CONTINUE
DO 7 i=0,M
FBN(l,0)=5.823d0!umol/L; initial concentration of fibrin in clot 
CONTINUE
DO 8 l=0,M
MESKb(l,0)=0.0d0
CONTINUE
lumol/L; Initial concentration of MESK in clot
Begin time (J) and position (I) iterations.
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38 DO 40 J=0,N 
TIME=J*dt
IF Q.LE.N) THEN
DO 50 i=Q,M
IF (i.EQ.O) THEN 
GOTO 11 
ELSE IF (i.GT.O) THEN 
GOTO 15 
ELSE IF (i.EQ.M) THEN 
GOTO 20
END IF
c Fill matrix with values of concentration for each species based on the convection-diffusion
c equation with reaction and absorption influences.
c For MESK in the fluid phase (SKf);
15 MESKf(i,j+1)= MESKf(i,j) + dt'DMESK*0.5d0*((MESKf(i+1 j+1)
$ -2.0d0*MESKf(ij+1)
$ +MESKf(i-1j+1))/(dx'*2.0d0)
$ +(MESKf(i+1 j)-2.0d0*MESKf(i j)+MESKf(i-1 j))/(dx"2.0d0))
$ - dt*(vxXMESKf(i+1 .j)-MESKf(i-1 j))/(2.0d0'dx))
$ -(1.1d-3'(Kdissolve*TIME)**3.0d0)
$ -dt*(((1.0dO-EPS)/EPS)*MESKb(ij))
$ + dt*(-Kdissolve*MESKf(ij))
c For streptokinase In the fluid phase (SKf):
SKf(ij+1)= SKf(ij) + dt*D*0.5d0*((SKf(l+1 j+1)-2.0d0*SKf(ij+1)
$ +SKf(i-1j+1))/(dx**2.0d0)
$ +(SKf(i+1 ,j)-2.0d0'SKf(i j)+SKf(i-1 .j))/(dx'*2.0d0))
$ - dt*(vx*(SKf(i+1 j)-SKf(i-1 J))/(2.0d0*dx))
$ - dt*(((1.0d0-EPS)/EPS)*0.0)
$ + dr(-K1*SKf(l.j)*PLGf(i,D + KM1'SKPLGf(ij)
$ + Kdissolve‘MESKf(ij))
$ + (1.1d-3*(Kdissolve*TIME)**3.0d0)
c For plasminogen in the fluid phase (PLGf):
PLGf(ij+1)= PLGf(ij) + dt*D*0.5d0*((PLGf(i+1j+1)-2.0d0*PLGf(ij+1)
$ + PLGf(i-1 j+1))/(dx**2.0d0)
$ +(PLGf(i+1J)-2.0d0*PLGf(ij)+PLGf(i-1,j))/(dx**2.0d0))
$ . dt*(vx*(PLGf(i+1 ,D-PLGf(i-1 .j))/(2.0d0*dx))
$ -dt*(((1.0d0-EPS)/EPS)*0.0)
$ + dt*(-K1 'SKf(i,j)'PLGf(i j)  + KM1*SKPLGf(i j)
$ - K2'PLGf(i j)*SKPLGf(i j))
c For streptokinase-plasminogen complex in the fluid phase (SKPLGf):
SKPLGf(ij+1)= SKPLGf(ij) + dt'D'0.5d0'((SKPLGf(i+1 j+1)
$ - 2.0d0'SKPLGf(i j+1) + SKPLGf(i-1 j+1))/(dx"2.0d0)
$ +(SKPLGf(i+1j)-2.0d0*SKPLGf(ij)
$ +SKPLGf(i-1j))/(dx**2.0d0))
$ - dt*(vx'(SKPLGf(i+1 j)-SKPLGf(i-1 j))/(2.0d0*dx))
$ -dt'(((1.0d0-EPS)/EPS)'SKPLGb(ij))
$ + dt'(K1 'SKf(i j)*PLGf(i j)  - KM1*SKPLGf(i,D
$ - K2*PLGf(i j)'SKPLGf(i,j))
c For plasmin in the fluid phase (PLMf):
16 PLMf(ij+1)= PLMf(lj) + dt*D*0.5d0*((PLMf(i+1 j+1)
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$ - 2.0dO*PLMf(i j+1) + PLMf(i-1 j+1))/(dx^.OdO)
$ +(PLMf(i+1j)-2.0d0TLMf(ij)
$ + PLMf(l-1 j))/((br2.0d0))
$ -dr(vx'(PLMf(i+1j)-PLMf(i-1,j))/(2.0cl0'dx))
$ - dt*(((1 OdO - EPS)/EPS)*PLMb(i j))
$ + dr(-K3'PLMf(i j) + K2*PLGf(IJ)'SKPLGf(ij))
c MESK IN THE FLUID PHASE
c Left boundary condition for MESK in fluid phase
11 MESKf(0 j+1)=MESKf(i j)  + dt*DMESK*0.5d0'((2.0d0*MESKf(i+1 j+1)
$ -2.0d0*MESKf(ij+1))/(dx*^.0d0)
$ + (2.0d0*MESKf(i+1,j)-2.0d0*MESKf(ij))/(dx**2.0d0))
$ - dr(vx'(MESKf(l+1 j)-MESKf(l,j))/(2.0d0'dx))
$ -(1 .1  d-3*(Kdissolve'TIME)"3.0d0)
$ + dt'(-Kdissolve'MESKf(Oj))
c STREPTOKINASE IN THE FLUID PHASE
c Left boundary condition for SK in fluid phase
SKf(0j+1)=SKf(ij) + dTD'0.5d0*((2.0d0*SKf(i+1 j+1)-2.0d0 
$ * SKf(ij+1))/(dx**2.0dO)
$ + (2.0d0*SKf(i+1 j)-2.0d0'SKf(ij))/(dx"2.0d0))
$ + dr(-K1'SKf(0,j)'PLGf(0 j)  + KM1 'SKPLGf(0 j)
$ + Kdissolve*MESKf(0,j))
$ + (1.1 d-3'(KdissolveTIME)*3.0d0)
c PLASMINOGEN IN THE FLUID PHASE
c Left boundary condition for PLG in fluid phase
PLGf(0j+1) = PLGf(Oj) + dt*D*0.5d0*((2.0d0*PLGf(i+1 j+1)-2.0d0 
$ *PLGf(ij+1))/(dx"2.0d0) +
$ (2.0dO*PLGf(i+1j)-2.0dO*PLGf(ij))/(dx**2.0dO))
$ + dt*(-K1 'SKf(0 j)'PLGf(0,j) + KM1 *SKPLGf(Oj)
$ + -K2'SKPLGf(0j)*PLGf(0j))
c STREPTOKINASE/PLASMINOGEN COMPLEX IN THE FLUID PHASE
c Left boundary condition for SKPLG in the fluid phase
SKPLGf(0j+1)=SKf(0j)
c PLASMIN IN THE FLUID PHASE
c Left boundary condition for PLM in the fluid phase
PLMf(0j+1)= PLMf(1 j)
$ - dt*((1.0d0-EPS)/EPS)*PLMb(0j)
$ + dt*(-K3'PLMf(M j)  + K2*PLGf(Mj)'SKPLGf(Mj))
c For plasmin in the solid phase (PLMb):
17 PLMb(lj+1)= PLMb(ij)
$ + dt*(KaPLMf*PLMf(l j)*(ThetaPLMb
$ - PLMb(ij)) - (KdPLMTPLMbOj)))
c For streptokinase-plasminogen complex in the solid phase (SKPLGb):
SKPLGb(ij+1)= SKPLGb(ij)
$ + dt'(KaSKPLGf*SKPLGf(ij)
$ '(ThetaSKPLGb-SKPLGb(lj))-KdSKPLGf*SKPLGb(ij))
c For MESK in the solid phase (MESKb):
MESKb(ij+1)= MESKb(ij)
$ + dt'(KaMESKrMESKf(lj)'(ThetaMESKb
$ - MESKb(ij)) - (KdMESKf»MESKb(ij)))
20 IF (i.EQ.M) THEN
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c MESK IN FLUID Right side (M):
MESKf(M.j+1)= MESKf(Mj) + dt*DMESK*(0.5d0*(2.Od0*MESKf(M-1 j+1)
$ -2.0dO*MESKf(Mj+1))/(dx"2.0dO)
$ + (2.0d0'MESKf(M-1,D-2.0d0'MESKf(M.j))/(dx**2 OdO))
$ -(1.1d-3*(KdissolveTIME)**3.0d0)
$ + dr(-K1'SKf(M,j)'PLGf(M,j) + KM1*SKPLGf(Mj)
$ - Kdissolve*MESKf(M,j))
c STREPTOKINASE IN FLUID Right side (M):
SKf(M,j+1)= SKf(MJ) + dt*D'(0.5d0*(2.0d0'SKf(M-1 j+1)-2.0d0 
$ *SKf(Mj+1))/(dx"2.0d0)
$ + (2.0dO*SKf(M-1,j)-2.0dO'SKf(Mj))/(dx**2.0dO))
$ + dt'(-K1 *SKf(M j)'PLGf(M,D + KM1 'SKPLGf(M,j)
$ + Kdlssolve'MESKf(Mj))
$ +(1.1d-3*(Kdlssolve*TIME)*'3.0d0)
c PLASMINOGEN IN FLUID Right side (M):
PLGf(Mj+1) = PLGf(Mj)
$ + drD*0.5d0*((2.0d0*PLGf(M-1 j+1 )-2.0d0
$ *PLGf(Mj+1))/(dx"2.0d0)
$ + (2.0d0*PLGf(M-1 j)-2.0d0*PLGf(Mj))/(dx'^.0d0))
$ + df(-K1'SKf(M j)'PLGf(M j) + KM1'SKPLGf(Mj)
$ - K2'SKPLGf(M j)'PLGf(M j))
c STREPTOKINASE-PLASMINOGEN COMPLEX IN FLUID Right side (M):
SKPLGf(Mj+1)= SKPLGf(Mj) + dt*D'0.5d0'((2.0d0*SKPLGf(M-1 j+1)
$ -2.0d0'SKPLGf(Mj+1))/(dx*^.0d0)
$ + (2.0d0*SKPLGf(M-1 j)-2.0d0*SKPLGf(iJ))/(dx**2.0d0))
$ -dt'((1.0d0-EPS)/EPS)*SKPLGb(Mj)
$ + dt*(K1 'SKf(M j)'PLGf(M,j)-KM1 *SKPLGf(M j)
$ - K2'SKPLGf(M j)*PLGf(M,j))
c PLASMIN IN FLUID Right side (M):
PLMf(Mj+1)= PLMf(Mj) + dt*D*0.5d0*((2.0d0*PLMf(M-1 j+1)
$ - 2.0d0*PLMf(Mj+1))/(dx**2.0d0)
$ + (2.0d0'PLMf(M-1 j)-2.0d0*PLMf(ij))/(dx*'2.0d0))
$ - ((1.0d0-EPS)/EPS)*PLMb(Mj)
$ + d t\-K 3TLM f(M j) + K2'PLGf(M j)*SKPLGf(M j))
END IF
c FIBRIN IN THE SOLID PHASE (FBN):
18 FBN(ij+1)= FBN(ij) + dt'(-K4'PLMb(lj)*FBN(ij))
write (*,*) ij
c Put the desired results in a file titled "GNResultsMESK"
OPEN (unit=6,file='CNResultsMESK.xls')
IF (SKf(i,j).LT.1.0d-10)THEN 
SKf(ij)=O.OdO
END IF
IF (SKPLGf(ij).LT.1.0d-20) THEN 
SKPLGf(ij)=O.OdO
END IF
IF (SKPLGb(ij).LT.1.0d-20) THEN
SKPLGb(ij)=O.OdO
END IF
IF (PLGf(ij).LT.1.0d-20) THEN 
PLGf(ij)=O.OdO
END IF
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